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Dopamine and serotonin are two neurotransmitters that have strong functional interactions 
where one of the functions of serotonin is to inhibit the activity of dopamine. These 
neurotransmitters exert their actions through mediation of dopaminergic and serotonergic 
receptors, and the receptors in focus in the current study, are the dopamine D2 and serotonin 
5-HT2A receptors. Common for both receptors is that they are class A G-protein-coupled 
receptors consisting of seven transmembrane helices embedded in the lipid membrane of 
neurons.  
 
Imbalance and disruption of especially the dopamine system in the CNS may result in 
hallucinations, delusions, and lowered levels of motivation, which are important signs of 
schizophrenia and psychosis disorders. These disorders are treated with antipsychotic drugs 
that predominantly antagonize dopamine D2 and serotonin 5-HT2A receptors. Unfortunately, 
many patients on treatment with antipsychotics experience side effects like sedation, weight 
gain and extrapyramidal disturbances. Therefore, there is a need of more effective 
antipsychotic drugs with less adverse effects. The main aim of this thesis is to get a deeper 
understanding of the mechanisms of action and side effects of antipsychotics.   
 
37 antipsychotic drugs were docked with induced fit docking (IFD) into four aminergic 
receptors, dopamine D2, serotonin 5-HT2A, 5-HT2C and histamine H1 receptor, scored 
according to energies associated with specific poses and finally ranked. Molecular dynamic 
(MD) simulations were further applied to thoroughly investigate the differences and 
similarities in binding modes between bromocriptine (agonist), aripiprazole (partial agonist) 
and risperidone (antagonist) in complex with the dopamine D2 receptor, in addition to 
pimavanserin in complex with the serotonin 5-HT2A receptor.   
 
Our results suggest that there is a link between the binding affinities of the antipsychotic 
drugs to different aminergic receptors, and the most common side effect observed. 
Additionally, MD simulations revealed that antipsychotic drugs with different intrinsic 
activity, bind to the dopamine D2 receptor in distinct ways. An agonist like bromocriptine on 
the dopamine D2 receptor, established stable hydrogen bonds to serines in TM5 (Ser5.43, 
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1 Introduction 
1.1 The Nervous System 
 
The human body consists of many complex organ systems from the integumentary, skeletal, 
muscular, endocrine, cardiovascular, lymphatic, respiratory, urinary systems to the nervous 
system. The nervous system is also the most complicated and comprehensive one as it is 
involved in all mentioned systems as the controlling, regulatory and communicating entity 
(1). Moreover, the nervous system is principally divided into two major regions, the central- 
and the peripheral nervous systems. The spinal cord and the brain are connected together and 
constitute what we call the central nervous system (CNS). This region is the executive control 
system in the body. The rest of the nervous structures in the body goes under the peripheral 
system, PNS, which mainly connects the central nervous system to muscles, organs, limbs 
and skin (2).  
Shortly explained, the PNS can be divided into two subsystems named the autonomic and 
somatic nervous system. The somatic nervous system has voluntary control over the skeletal 
muscles, bones and skin while the autonomic nervous system has involuntary control over 
cardiac muscles, glands and smooth muscles found in many organs and blood vessels. This 
means that the functions of the autonomic nervous system are regulated and performed 
without our minds being involved and independently of our wishes. In this thesis we are 
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1.2 The Central Nervous system  
 
The central nervous system coordinates our actions, reflexes and sensations and consists of 
the brain and the spinal cord.  While the brain is the “headquarters”, the spinal cord acts as the 
“highway” for communication that combines the brain and the body (3). A vast network of 
cranial nerves from the PNS contains sensory receptors that are linked to the brain which 
again aids in processing changes in both external and internal environments. Nervous tissue 
consists of nerve cells, also referred to as neurons and is the largest and most important group 
of tissues in the nervous system. A neuron is built up of the cell body called soma. Dendrites 
and axons are extensions from the cell body that either pass or receive information from 
nearby neurons. In addition to nerve cells, neuroglial/glial cells are just as important but 
outnumbers neurons by a 3 to 1 ratio (3).  
The major distinction between neuroglial and nerve cells is that glial cells do not participate 
directly in synaptic transmission nor electrical signalling, however they provide a framework 
of tissue that supports the neurons and their activities. Further, glial cells are also important in 
responding to tissue damage and maintaining the concentration of important chemical 
substances. They also play an essential role in what is known as the blood-brain barrier, BBB 
which is fundamental in drug delivery to the brain. The brain is an immune privileged organ 
that must be protected at all costs. The BBB is thereby present in the vasculature of the brain 
and one of the two systems involved in maintaining brain homeostasis. This is a physiological 
barrier that acts as a security system and protects neural tissues from exogenous substances 
like pathogens and toxins (4). It further separates circulating blood from cerebrospinal fluid of 
the brain (5). Structurally, the BBB consists of different classes of cells including mural cells, 
endothelial cells, glial cells and contractile proteins that can contract or stretch to regulate the 
diameter of the blood vessel. A simplified illustration of the barrier is provided in figure 1. 
Vital small molecules however, such as oxygen, hormones and carbon dioxide have free 
passage through the BBB. The other system involved in maintaining brain homeostasis is 
called the complement system and is a part of the immune system.  
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Figure 1: simplified illustration of the blood-brain barrier in the brain. The BBB is composed of an inner lining of 
endothelial cells shown in purple, blood cells and mural cells that wrap around the endothelial cells. The mural 
cells (in beige) in addition to the endothelial cells are important in regulating the vascular permeability controlling 
the molecules that enter the blood stream in the CNS (5). 
 
One of the challenges seen in pharmaceutical drug design that target CNS disorders, is 
connected to the difficulties substances experience when penetrating the blood-brain barrier. 
This has to some extent been solved by for example creating smaller lipid-soluble substances 
that can penetrate the blood-brain barrier easier by transmembrane diffusion as drugs with 
low molecular weight and sufficient lipid solubility are more effective in transmembrane 
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1.3 Signal transmission 
 
Endogenous neurotransmitters are chemical substances released by synaptic terminals which 
transmit signals between nerve cells upon binding to their respective receptors. These 
substances are fundamental for chemical cell to cell interactions and for control and 
regulation of behavioural and physiological functions (7). Most of the neurotransmitters are 
monoamines (e.g. dopamine, serotonin, histamine and noradrenaline), but there are also 
neurotransmitters that are simple amino acids like 𝛾-aminobutyric acid (GABA), glutamate, 
and glycine. Biogenic transmitters modulate activities requiring fast responses like for 
instance, the fight or flight response where noradrenalin in particular is prominent (8). As a 
result, they are also inactivated quickly by degrading enzymes or specific uptake transporters 
to prevent continuous activation. Usually, neurotransmitters are synthetized and stored in 
vesicles in the presynaptic neuron.  The release of the transmitters comes as a response to an 
action potential that has travelled along the axon and led to the opening of voltage gated 
calcium channels in the nerve terminal. The calcium ions (Ca2+) then cause these vesicles to 
fuse with the membrane and release its content in the synaptic cleft by exocytosis. Following 
release they bind to their appropriate receptors on the postsynaptic neuron where they can 
exhibit their functions by initiating cascades of secondary effects leading to their biological 
responses (9). 
The driving force for this process is the action potential. An action potential is caused by 
temporary changes in membrane permeability for diffusible ions. Neurons are filled with ions 
and at the resting state there is an equilibrium between cations and anions on the inside and 
outside. Potassium ions (K+) and sodium ions (Na+) are unequally distributed on the inside 
and outside of the neuronal membrane. The outer side of the neuron has a higher 
concentration of Na+ ions compared to the inside, while the inside of the neuron contains a 
higher concentration of K+ ions than the outside. In total, the extracellular space is more 
positively charged than intracellular. However, the concentrations are dynamic which means 
that ions constantly are flowing in and out of the neuron in an attempt of equalizing the 
concentration gradient. Despite of the attempt, at the resting membrane potential, the 
distribution of ions yields a net negative charge around approximately -70mV on the inside 
relative to the exterior.  
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In the initial step of neuron activation, hypopolarization, a few ion channels are open which 
allows Na+ ions to enter the nerve cell which then renders the intracellular space more 
positive and less negative. This leads to an increase in the membrane potential to around -55 
mV which influences the opening of voltage-gated sodium channels that causes an influx of 
Na+ ions. The influx of Na+ ions further make the neuron electropositive to + 30 mv. After 
this point, repolarization occurs which then brings the cell closer to the previous resting 
potential. The voltage-gated sodium channels get inactivated while specific potassium 
channels are activated simultaneously. Opening of the potassium channels leads to efflux of 
K+ ions from the neuron and the neuron once again loses positively charged ions and returns 
back to its resting state. Finally, hyperpolarization happens due to the delayed inactivation of 
potassium channels that still allows K+ ions to exit from the neuron. This causes the 
membrane potential to go even lower than the initial potential. As the potassium channels 
begin to close, the resting state is also re-established, and the process is repeated (10).   
Following synthesis of the respective biogenic amine transmitters in presynaptic neurons, the 
transmitters are loaded and stored in vesicles. An action potential arrives at the nerve terminal 
which promotes opening of calcium channels and finally release of neurotransmitters into the 
synaptic cleft by exocytosis. Henceforth, the neurotransmitters diffuse across the cleft and 
binds to the respective receptors postsynaptically, i.e., dopamine binds to dopamine receptors 
while serotonin binds to serotonergic receptors. When the neurotransmitter is bound to its 
receptor, it activates the receptor resulting in the biological effect. The actions of dopamine 
and serotonin in particular, are mostly terminated by reuptake back into surrounding cells by 
selective presynaptic transporters. The actions of acetylcholine on the other hand, are 
terminated by enzymatic degrading (11, 12). A summary of dopaminergic synaptic 
transmission in the nervous system is displayed in figure 2.  
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Figure 2: simplified illustration of the synaptic transmission in dopaminergic neurons. Dopamine (pink square) is 
released from the presynaptic terminal, diffuses over the synaptic cleft before it binds to and activates 
dopaminergic receptor (D1-D5). Dopamine is then taken up by transporters located presynaptically and finally 
broken down by enzymes such as catechol-O-methyltransferase (COMT) and monoamine oxidase B (MAO-B) 
(13). 
 
In this thesis the neurotransmitters dopamine and serotonin, also known as 5-
hydroxytrypamine are of particular interest because they tightly interact. Moreover, imbalance 
and disruptions of mainly the dopamine systems are responsible for many disorders including 
psychosis, schizophrenia and Parkinson´s disease.  
Supplementary, histamine for instance is also important due to the fact that some of the 
observed adverse effects of antipsychotic drugs are caused by unfavourable binding to 
histaminergic receptors and a subtype of serotonin receptors named the 5-HT2C receptor. An 
earlier study (14) mentioned that obesity, diabetes and metabolic syndrome were prevalent 
comorbidities in schizophrenia patients especially those on treatment with antipsychotics. It 
also stated that antipsychotic drugs could impair metabolic regulation as these drugs are 
strongly associated with the core components of metabolic syndrome i.e., dyslipidaemia, 
hypercholesterolemia, weight gain and a lesser degree of hypertension.  
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1.4 Dopamine and serotonin  
 
Dopamine is an essential neurotransmitter that is commonly studied for its role in 
physiological and cognitive functions including reward-based learning and movement but 
also disorders such as psychosis, Parkinson’s disease and addiction (15). This 
neurotransmitter is a full agonist that naturally binds to and activate dopamine receptors (16).  
In diseases like Parkinson’s disease, it is especially the presynaptic substantia nigra neurons 
that are degenerated leading to impaired signalling between dopamine and dopamine 
receptors, resulting in dopamine deficiency in striatum. Consequences of dopamine deficiency 
can be psychiatric and movement pathologies. The main pathways of dopamine, and the 
locations of the dopamine receptors are defined as the mesolimbic, mesocortical, tubero-
infundibular and nigrostriatal pathways and are all located within the central nervous system 
(17). 
The mentioned pathways are responsible for different regulations where impaired signal 
transduction of any of these, results in positive or negative psychosis symptoms. The 
mesocortical and mesolimbic pathways are in control of phenomena like desire, pleasure, 
motivation and reward. For instance, when the mesolimbic system is hyperactive, it can result 
in positive psychosis symptoms like hallucinations and delusions. The nigrostriatal pathway is 
the pathway that rather controls and regulates motor function. Coordination of body 
movement through the skeletal system is mainly regulated via inputs from the substantia nigra 
to the major dopamine-containing area, corpus striatum. A clinically relevant example is in 
the pathology of Parkinson’s disease where the dopaminergic neurons of substantia nigra 
degenerate leading to motor dysfunction symptoms like rigidity, tremor and bradykinesia. 
Secretion of the hormone prolactin is regulated from the anterior pituitary gland through the 
tubero-infundibular pathway. Situations where dopamine is not released properly or use of 
drugs such as antipsychotics that antagonize the dopamine D2 receptor, can lead to 
hyperprolactinemia causing disruption of the menstrual cycle in women and abnormal 
lactation or breast formation in both genders.  
The actions of dopamine are mediated by a family of G-protein-coupled receptors called 
dopamine receptors. This class of receptors constitutes 5 receptors and is further divided into 
D1-like (D1 and D5) and D2 like (D2, D3 and D4) receptors. The dopamine D2 receptor is of 
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particular interest in this thesis because it is the primary target for antipsychotic drugs. More 
on this is provided in later chapters.  
Serotonin, 5-hydroxytryptamine (5-HT) is primarily found within the raphe region of the pons 
and in the upper brainstem. Neurons from these areas have widespread projections to the 
forebrain as well. Serotonin is commonly studied for its role in the headaches, sexual 
behaviours, circadian rhythms, emotions, mental arousal and emotions. Similarly to 
dopamine, impairments or disruptions of the serotonergic neurons have been implicated in 
various psychiatric disorders such as anxiety disorders, depression and in some cases 
schizophrenia (18). The actions of serotonin are mediated through serotonin 5-HT receptors 
which are expressed throughout both the central and peripheral nervous system. In total, there 
are 7 groups divided into 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-HT7 receptors. 
Only 5-HT3 receptors are ligand gated ion channels while the rest are G-protein-coupled 
receptors. Further, the 5-HT2 group of receptors consists of 5-HT2A, 5-HT2B and 5-HT2C 
receptors that have similar ligand binding and signalling properties.  
 
 




1.4.1 Interplay between dopamine and serotonin  
 
In previous papers (19-21) it has been described that the there is an interplay between 
serotonin and dopamine in the central nervous system. One of the mechanisms of the 
interplay, involves serotonin ability to inhibit dopamine production as we know that indeed, 
neurotransmitters do not act independently. Numerous studies have indicated that dopamine 
and serotonin system interact closely at synaptic levels (22-24), explaining that serotonin 
hypofunction or impairment may represent a biochemical trait that predisposes individuals to 
neurological diseases due to dopamine hyperfunction. Further, in the same review (20), it was 
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suggested that dysfunctional interactions between dopamine and serotonin systems perhaps is 
an important mechanism underlying the link between comorbid disorders and impulsive 
aggression. Consequently, impulsive behaviours among other CNS disorders, are undoubtably 
promoted by hyperactivity of the dopamine system as a result of a deficient serotonergic 
function.  A modified stress model of impulsive aggression was proposed to further 
understand the interaction between the respective transmitters. Additionally, substance abuse 
associated with impulsive aggression is surely a result of dopamine dysregulation resulting 
from serotonergic deficiency.  
Behaviours related to addictions and withdrawals are thought to be determined by the balance 
between the serotonin and dopamine, where dopamine is further thought to stimulate 
appetitive behaviours while serotonin promotes the opposite. This also explains some of the 
metabolic side effects patients treated with drugs interfering with the respective 
neurotransmitters experience. Some of these side effects include weight gain and increased 
cholesterol. The dopaminergic neurons receive serotonergic projections which also promote 
functional modulation of the terminals and cell bodies of dopamine neurons. More 
specifically, prior research (20) demonstrated that dopamine activity is inhibited by serotonin 
5-HT2A receptors.  
 
1.5 Pathophysiology of psychiatric disorders  
 
Neurological disorders are according to the world health organization (25) and other sources 
(26, 27) defined as diseases that affect both the central and peripheral nervous systems. 
Disorders that fall into this category can range from everything between migraines to 
Parkinson’s disease, psychiatric disorders and multiple sclerosis. The world health 
organization further estimated in 2016 that neurological disorders and their consequences 
affected hundreds of millions of people worldwide and identified social discrimination and 
health inequalities such as wealth and power as major factors contributing to the associated 
disability and suffering (25).   
Generally speaking, without differentiating between the various disorders, abnormalities in 
biochemical, structural and electrical system within the nervous system can result in a broad 
spectre of symptoms. Examples of symptoms include delirium, hallucinations, headache, pain 
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and altered levels of consciousness. Whilst the central nervous system is surrounded and 
protected by membranes, bones and isolated by the blood-brain barrier, it is still prone to 
damage or disruption if compromised.  
Genetic disorders, infections, trauma, degeneration, environmental factors, lifestyle, health 
problems like malnutrition and even gluten sensitivity are among some of the proposed causes 
to neurological disorders (28). CNS issues may also be a result of injuries or problems in 
other parts of the human body as the whole body interacts with the nervous system. For 
example, problems with the cardiovascular system (blood vessels) that also supply the brain 
with blood, can lead to brain injuries due to insufficient blood supply.  
Neurological disorders can be looked at as a tree. One of the branches from this tree, can be 
named psychiatric illnesses or mental disorders. Disorders in this category appear primarily as 
abnormalities of feelings, behaviour or thoughts like delusions, delirium, cognitive failure and 
hallucinations (27). In many cases, over time and depending on severity, these symptoms can 
produce distress or impairment of function. Examples of psychiatric disorders include 




Psychoses such as schizophrenia are amongst the most severe mental illnesses and it often 
affects young people, is often chronic and is usually highly disabling (18). Schizophrenia is 
an example of a complex disorder that involves dysregulation and disruption of multiple 
pathways, especially dopaminergic systems. Deficits in acetylcholine muscarinic neurons and 
inflammation have been identified to play major roles in the development and exacerbation of 
schizophrenia. In addition, genetics are equally as important as there is a strong hereditary 
factor in the aetiology of schizophrenia (18).  
The evidence suggestive features of schizophrenia mainly include what can be divided into 
cognitive, positive and negative symptoms (11). Positive symptoms are defined as symptoms 
that for instance are added to ones personality. Delusions, hallucinations, thought disorders, 
troubles with mobility and abnormal behaviours are amongst the most prominent positive 
symptoms. On the contrary, negative symptoms often reduces ones previous demeanour and 
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can include withdrawal from social contacts, reluctance to perform activities that once where 
fun, inability to experience pleasure and a reduction in emotional responses. The cognition 
aspect of schizophrenia often involves issues with memory and attention. Supplementary to 
the mentioned symptoms, anxiety, depression, and guilt are often present and in severe cases, 
some patients become suicidal (18).  
A combination of genetic and environmental factors is believed to be the causes of 
schizophrenia. This is in view of the fact that a person may have a genetic trait that 
predisposes them for schizophrenia but exposure to certain environmental factors like viral 
infections, toxins or highly stressful situations are required for the disorder to develop (29). In 
addition to the genetics and environmental factors, there is a robust association with the 
neurochemical basis of schizophrenia because some of the affected genes control neuronal 
development, synaptic connectivity and neurotransmission. Different symptoms appear to be 
a result from malfunctions of different neuronal circuits.  Decreased dopamine activity in the 
mesocortical pathway for example, is associated with negative symptoms while 
overactivation of dopamine receptors in the mesolimbic pathway is associated with positive 
symptoms (18).   
In the medical field, preventative measures and rehabilitation in the form of therapy, pain 
management and in some situations, switching to a ketogenic diet are recommended and 
preferred. However, practicing this is extremely challenging so the introduction of 
medications to assist, is a quite common intervention. The class of medication used to treat 
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1.6 Antipsychotic drugs 
 
Antipsychotic drugs, also named neuroleptics, are drugs used to treat and alleviate symptoms 
of psychotic disorders such as schizophrenia. Further, antipsychotic drugs are divided into 
typical or atypical, also known as first- and second-generation antipsychotics respectively. 
Typical antipsychotics (TAPs) work by antagonizing the dopamine D2 receptor in all four 
dopamine pathways. In hyperactive mesolimbic pathways, the use of typical antipsychotics 
results in reduction in positive psychosis symptoms like hallucinations and delusion. 
Examples of substances in this class include haloperidol and chlorpromazine. In contrast to 
typical agents, atypical antipsychotics (AAPs) are weak D2 receptor antagonists in addition to 
5-HT2A receptor antagonists. Risperidone, olanzapine, quetiapine and aripiprazole are among 
the most frequently used atypical antipsychotic drugs (30).   
A ligand that works as a full agonist binds to its respective receptor and alters the receptor 
state which then results in a biological response. These ligands stabilize an active 
conformation of the receptor and increase receptor activity. A full agonist has in other words 
the capability of inducing a maximal response on its receptor. Contrarily, drugs that promote 
the antipsychotic effect mainly antagonize dopamine D2 receptor activation and prevent 
dopamine from binding, also known as competitive dopamine D2 receptor antagonism. 
Inverse agonists like risperidone stabilize an inactive state conformation of the receptor. 
Further there are for instance D2 receptor partial agonists that can modulate dopaminergic 
neurotransmission by producing the biological effect but at a much lower efficacy compared 
to a full agonist (31). A proposed mechanism explains that a partial agonist bind to the active 
site in a way that does not induce an ideal conformational change and receptor activation is 
therefore decreased (32). Alternatively, such pharmacologically active drugs don’t have the 
ability to elicit as large an effect, even at high concentrations so that all receptors would be 
occupied, as can a full agonist (33), figure 4. 
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Figure 4: comparison between full agonist in red and partial agonist in blue. The half maximum effective 
concentrations EC50 and the maximum effective concentration Emax are marked with dotted lines.(34).   
 
Aripiprazole has a mechanism of action that is quite different from other antipsychotic drugs. 
It exerts its actions through partial agonism on both serotonin 5-HT1A and dopamine D2 
receptors and also act as an antagonist on the serotonin 5-HT2A receptor. Though aripiprazole 
was introduced in therapy over 15 years ago, the complexity of its action on signal 
transduction remains unresolved (35). Still new proposals in attempts to explain the 
mechanism of action of aripiprazole are presented, one of them which suggests that the term 
partial agonist is not sufficient. Rather, the conceptualization of this agent has shifted to 
“functional selectivity” referring to aripiprazole ability to display antagonistic and agonistic 
effects on dopamine D2 receptor signalling pathways (35).  It is suggested that aripiprazole 
may act as a agonist when dopamine concentrations are low and act as a antagonist when 
dopamine concentrations are elevated (36).  
In clinical practice, the choice between using atypical or typical antipsychotics in treatment of 
patients is very complex and mostly dependent on the experience of the physician, the 
patients symptoms and conditions. Yet, there have been several studies (37-39) where the 
antipsychotics systematically have been compared in regards of clinical effect, tolerability, 
risk of side effects and quality of life. The conclusion from these studies was that atypical 
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antipsychotics such as olanzapine, risperidone and clozapine demonstrated a better outcome 
in aspects like improved pharmacological profile in reducing both negative and positive 
symptoms compared to typical antipsychotics (39). A portion of these results however, 
possibly owes to the absence/reduce in extrapyramidal symptoms which minimize the risk of 
developing secondary (negative) symptoms (40).  
 
1.6.1 Unwanted effect of antipsychotic drugs 
 
Unfortunately, many antipsychotic drugs produce serious and unacceptable side effects due to 
promiscuous activities against related receptors. Motor disturbances, collectively termed 
extrapyramidal side effects, include acute dystonia (involuntary movements like restlessness 
and muscle spasm), tremor and tardive dyskinesias and are among the main side effects 
antipsychotic drugs produce. Many of these extrapyramidal side effects are caused by 
dopamine D2 receptor antagonism in the nigrostriatal pathway and is a common disadvantage 
of typical antipsychotics (11). In addition to antagonizing dopamine D2 receptors, newer 
atypical agents concomitantly antagonize serotonin 5-HT2A receptors which to some extent 
mitigates motor disturbances. It has been suggested that this is due to their differential binding 
kinetics and higher affinity for the 5-HT2A receptor (41). 
Apart from motor disturbances, endocrine, metabolic and sedating effects are commonly 
reported in patients treated with antipsychotic drugs. Abnormal breast growth in both genders, 
is a result of antagonism of dopamine D2 receptors in the pituitary gland which again increase 
prolactin plasma concentration because dopamine inhibits prolactin secretion. Additionally, 
hyperprolactinemia is sometimes accompanied with estradiol reduction in women which 
could lead to increased appetite (18). Both TAPs and AAPs can disrupt metabolic regulation 
both in the central- and peripheral organs by activating the hunger centers and inhibiting 
satiety sensation. For instance, lipid and glucose metabolism in the liver can become impaired 
with weight gain leading to obesity. Results of this include increased risk of diabetes and 
cardiovascular diseases (30, 42).  
On a molecular level, the mentioned adverse effects of antipsychotics stem from interactions 
with various receptors such as dopamine D2, histaminergic H1, 1 adrenergic, serotonin 5-
HT2A/2C and acetylcholine M1/M3 muscarinic receptors (32). Altered dopaminergic signalling 
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is a ubiquitous contributor to metabolic effects partially because dopamine regulates feeding 
behaviour. Overconsumption of palatable food seem to decrease dopamine D2 signalling 
because the reward system adapts. This means that dopamine depletion could induce 
overeating. Serotonin modulates peripheral metabolism and circadian rhythms among others 
(43, 44). Additional antagonism of serotonin 5-HT2A and 5-HT2C receptors could induce 
hunger and increase food intake promoting weight gain. By altering serotonergic efflux in 
different brain regions, antipsychotic drugs can disturb serotonergic regulation of metabolic 
homeostasis and contribute to metabolic effects like increased glucose-dependent insulin 
secretion (45).  
Drowsiness, sedation, dizziness, dry mouth and headaches are more examples of common 
adverse effects that many patients experience, again due to the fact that more antipsychotic 
drug are not fully selective and limited to specific receptors, hence they interfere with several 
molecular systems (11).   
Finally, agranulocytosis and neutropenia are rare, yet severe adverse effects that are seen 
more frequently with clozapine (AAP) compared to other antipsychotic drugs in the same 
class and compared to conventional antipsychotics (11, 18). These adverse effects are 
reversible upon promptly withdrawal and are estimated to occur in 1-2 percent of patients 
treated with clozapine (32). Both agranulocytosis and neutropenia can be fatal and therefore 
require regularly hematologic monitoring. In refractory schizophrenia and treatment-resistant 
psychoses, clozapine is considered the gold standard, so the associated adverse effects are 
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1.7 G-protein-coupled receptors 
 
GPCRs, which stands for G-protein-coupled receptors, form a large group of membrane-
bound receptors that mediate cellular responses in response to activation by ligands such as 
neurotransmitters, proteins, neuropeptides, ions, lipids, nucleotides and hormones. More than 
800 human GPCR sequences have been identified and they are categorized into six classes A 
to F, based on function and amino acid sequence (48). Class A GPCRs, also known as 
rhodopsin-like receptors, accounts for the largest and most diverse class of GPCRs found in 
humans (49). The architecture of class A is quite simple and both the ligand binding site and 
binding site of G-protein is located in the 7TM domain (seven transmembrane). The 
endogenous ligands on class A GPCRs include most biogenic amine neurotransmitters (such 
as histamine, dopamine, noradrenaline, histamine and serotonin), purines, cannabinoids and 
hormones among others (18). Class B GPCRs, also called the secretin and adhesion family, 
are mainly activated by peptides and hormones like glucagon, secretin and incretins. These 
receptors are characterized by their long amino-terminals and are important drug targets in 
diseases such as diabetes, psychiatric disorders and osteoporosis (50). Ligands are mainly 
recognized by a binding site in the extracellular domain and an additional binding site is 
found within the 7TM domain (51).  
Metabotropic glutamate and GABAB receptors are examples of Class C GPCRs which are the 
receptors for the inhibitory and excitatory neurotransmitters GABA and glutamate 
respectively. In contrast to class A receptors, the orthosteric binding site in class C GPCRs is 
situated in an amino-terminal Venus flytrap domain which consist of two distinct lobes that 
close around the ligand (48). The allosteric site is located deep into the 7TM domain (52). 
Further, class D GPCRs – fungal mating pheromone receptors and class E being cAMP 
receptors, don’t exist in humans and are believed to have many structural differences 
compared to class A GPCRs. One of these differences is that the highly conserved disulphide 
bond established between Cys(ECL2) and Cys(3.25) is not found in class D GPCRs (53). 
Finally, lipoglycoprotein Wnt is the endogenous ligand of class F frizzled/smoothened 
receptors. Class F receptors possess a long amino-terminal domain that is rich in cysteine 
residues and also holds the ligand binding site (48). 
Common for all classes of GPCRs, is that they consist of seven hydrophobic transmembrane 
(TM) helices linked by three intracellular and three extracellular loops. The 7TM helices are 
 
Page 27 of 116 
embedded within the membrane and forms a cavity that resembles a barrel. On the 
intracellular side is a carboxyl terminal (C-terminal) and an amino terminal (N-terminal) is 
located on the extracellular side. Both the C- and the N- terminal of the receptors are believed 
to be the most variable (54). Relevant for this project are dopamine D2 and serotonin 5-
HT2A/2C receptors which are classified as class A GPCRs.  
 
1.7.1 Structure of class A GPCRs 
 
Class A GPCRs share a common structural signature which consist of a heptahelical 
transmembrane domain. This domain is connected by three intracellular (ICL) and three 
extracellular loops (ECL) that are important for receptor function because they provide 
structure to the extracellular region, mediate movement of the helices and contribute to 
protein folding. The second extracellular loop, ECL2 in particular, has been known to be of 
significance for ligand binding as well as receptor activation (55-57).  
Some parts of the GPCRs are more conserved among the diverse family of GPCRs and the 
residues that are important for transduction of the signal from the agonist binding site to the 
G-protein are conserved (49). The most variable segments, however, are the terminuses, both 
the amino and carboxyl terminus. In addition, great diversity is also observed for the 
intracellular loop (ICL3) between TM5 and TM6 (54). Monoaminergic class A GPCRs such 
as dopamine, serotonin and histamine receptors, have a disulphide bridge that constrains the 
ECL2 on top of the orthosteric binding site. Position identifiers based on the Ballesteros-
Weinstein numbering scheme are used throughout this thesis to easily identify corresponding 
residues across class A GPCRs (58). In the dopamine D2 receptor, two conserved residues 
Asn186(5.35) and Ile184(ECL2) are engaged in interactions with ligands and other residues 
in the binding site (59).  
Aspartic acid residue 3.32 in TM3 is conserved among biogenic amine receptors and provides 
a strong salt bridge interaction with protonated amine in ligands. Other important residues 
that are as conserved are mentioned in later chapters. The binding site for the G-protein is 
located on the intracellular side and involves the carboxyl terminus. The most conserved 
regions of class A GPCRs can be summarized in the microswitch motifs CWxP, PIF, Na+ 
pocket, NPxxY and DRY where the letters of the motifs stand for the residues and “x” 
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denotes any residue. For instance, CWxP (Cys, Trp, Pro) is situated in TM6, the PIF motif 
(Pro, Ile, Phe) combines TM5, TM6 and TM3, DRY (Asp, Arg, Tyr) and NPxxY (Asn, Pro, 
Tyr) motifs are located in TM3 and TM7 respectively (49). The NPxxY motif is known as the 
activation switch that moves inward during activation of the receptor. The ionic lock is a 
molecular switch formed between the highly conserved amino acids Arg(3.50) and 
Glu/Asp(6.50) from the D/ERY motif. In the inactive state of the receptor, the ionic lock is 
established (ionic interaction between mentioned amino acids) while the ionic lock is broken 
upon activation of the receptor as a result of outward movement of TM6 that allows for the 
binding of a G-protein (60).  
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1.7.2 Activation of class A GPCRs 
 
For class A GPCRs, the binding site for endogenous ligands is formed between the seven 
transmembrane helices accessible from the extracellular surface. An additional binding site 
located on the inner surface of the receptor, opens up for the binding of a G-protein upon 
binding of endogenous ligands in the primary binding site. Binding of a ligand to the receptor 
induces conformational changes in the GPCRs which results in the binding of either GTP-
binding proteins or the adaptor proteins called arrestins. 
G-proteins consisting of three heteromeric subunits (,  and ) are anchored to the 
membrane through attached lipid residues. Coupling of -subunit to the receptor causes the 
bound guanosine diphosphate (GDP) to be replaced by guanosine triphosphate (GTP). The -
GTP complex then dissociates from the - complex and further interacts with effector 
proteins such as adenylyl cyclase or phospholipase C, resulting in either increased or 
decreased level of secondary messengers and ions which ultimately produce the cellular 
response (18).   
Conformational change in the associated G-protein, triggers the release of GDP from the -
subunit, which is then replaced by GTP, as a result of receptor activation. This leads to that 
the -GTP complex dissociates from the - subunits and binds to a target enzyme or ion 
channel which then in return promotes inhibition or activation. The - complex also 
mediates effects by stimulating or inhibiting effector proteins like ion channels and kinases. 
The G-protein is returned to inactive state within a short period of time as the -subunit 
reassociate with the - subunits. Adenylyl cyclase, an enzyme that catalyse the conversion of 
ATP to cAMP (cyclic AMP), is either activated by Gs protein or inhibited by the Gi protein. 
Upon activation, cAMP further activates protein kinase A by triggering the dissociation of 
regulatory subunits (, and ) from the catalytic subunit. The catalytic subunits stimulate 
other target proteins through phosphorylation which then trigger the cellular response. A 
GPCR coupled to a Gi protein, which inhibits adenylyl cyclase, counteracts the actions of a 
GPCR coupled to Gs. Ultimately, the magnitude of the cellular response is proportional to the 
concentration of cAMP. Reduction in cAMP concentrations through active export or 
simultaneous enzymatic degradation result in the termination of the signal.  
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Another activation route for which GPCRs exert its action, involves the PI-PLC 
(Phosphatidylinositol phospholipase C) pathway. In this case the receptor is coupled to a Gq 
protein which activates the production of the secondary messengers DAG (diacylglycerol) 
and IP3 (inositol triphosphate). DAG is lipid soluble and remains in the membrane. IP3 on the 
other hand is water soluble and therefore diffuses into the cytoplasm where it triggers the 
release of calcium from intracellular storages. Released calcium can further bind to several 
intracellular proteins that through phosphorylation, stimulate a broad range of specific kinases 
among other (11). Figure 6 presents a summary of the activation mechanisms of GPCR. 
 
Figure 6: activation mechanism of GPCR (13). 
 
The other signalling pathway that can be activated and mediated through GPCRs, involves the 
binding of arrestins which functions to silence GPCR signalling and induce receptor 
internalization (61). In order for an arrestin to bind to the GPCRs, the receptors have to be 
phosphorylated by certain kinases before arrestins then can activate their own signalling 
independent of G-protein. This includes activation effector proteins that regulate cellular 
proliferation, apoptosis and differentiation. Receptor internalisation occurs through arrestin 
coupling and the receptor can then be dephosphorylated and reinserted into membrane. 
Alternatively, the receptors can be brought into lysosomes for degradation as an effect of 
arrestin binding (18). Regarding the structure of arrestins, a structural study revealed that 
arrestins are elongated molecules consisting of two domains with large N- and C-terminals 
(62). Interestingly, some ligands have been identified to favour one signalling pathway over 
the other in a concept known as biased signalling or functional selectivity. This means that 
certain ligand-receptor complexes (on the same receptor) preferentially signal through either 
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the arrestin or G-protein pathway with distinct efficacies and potencies which ultimately have 
distinct functional consequences (63).   
 
1.7.3 Dopamine receptors 
 
Human dopamine receptors, are mainly found within the central nervous system and 
especially expressed in the striatum, substantia nigra, hypothalamus, cortical areas, amygdalae 
and hippocampus (32). Dopaminergic neurotransmission have important roles in emotions, 
learning ability, addiction and the reward. The human dopamine receptors are class A GPCRs 
and also main targets for antipsychotic drugs. Imbalance of dopamine concentration in the 
CNS has been shown to be an important factor in disorders such as addiction, Parkinson’s 
disease, bipolar disorder and schizophrenia (15).  
The essential actions of dopamine are mediated by dopamine D1-D5 receptors which are 
closely related, have overlapping functions and pharmacology as well as conserved key 
residues (64). However, dopamine D1 and D5 receptor are located on both the pre-and post-
synaptic neurons while dopamine D2-D4 receptors predominantly are located post-
synaptically (65). An overview table of dopamine receptors is provided in supplementary 
material. Further, focusing on the dopamine D2 receptor due to the fact that it is the most 
relevant in this thesis, it is interesting to notice that there are two isoforms of this receptor 
named D2S (short) and D2L (long). The short version is distributed in the mesencephalon and 
hypothalamus regions whereas the long type is mainly present in the striatum (66).  
According to earlier publications (64, 67), the predicted binding site for agonists in the 
dopamine D2 receptor is formed within the most hydrophobic segments of the seven 
membrane-spanning helices TM3, TM4, TM5 and TM6. The binding site crevice is extending 
from the extracellular surface of the receptor into the transmembrane domain in addition to 
this crevice being water accessible. Thus, the binding site is accessible to water soluble 
agonists like dopamine. Some of the conserved features in class A GPCRs, like the dopamine 
D2 receptor that contribute to agonist binding, firstly include an electrostatic interaction 
between aspartic acid (Asp114(3.32)) in the third transmembrane (TM3) and protonated 
amine of the ligand. Secondly, serines in TM5 (Ser5.43, Ser5.42 and Ser5.46), form hydrogen 
bonds with polar atoms of the ligand while the hydrophobic aromatic cluster present in TM6 
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interact with aromatic features of the ligand (68). Another interesting feature especially 
observed in the dopamine D2 receptor, is a hydrophobic pocket for antagonist located in TM7 
and lastly the second extracellular loop which includes Ile184(ECL2) and Ile183(ECL2). 
 
Figure 7: three-dimensional (3D) structure of the dopamine D2 receptor. Agonist bromocriptine (green sticks) is 
bound in the ligand binding site and binding site residues are shown in gray with labels. Structure is based on 
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1.7.4 Serotonin receptors 
 
Here we are focusing on the receptor subtypes of the serotonin 5-HT2 class, serotonin 5-HT2A 
receptor and 5-HT2C receptor. Serotonin has been implicated in the pathogenesis of 
depression. It is a fact that suicidal and depressed patients have a depletion in the levels of 
serotonin and other monoamine neurotransmitters in the CNS compared to normal individuals 
which means serotonin concentrations in these patients are inadequate (70). The goal of 
antidepressant therefore is to increase the concentrations of monoamines, serotonin and/or 
noradrenaline in the synaptic cleft to further increase the biological functions e.g., through 
inhibiting reuptake of monoamines. 
Uniformly to dopamine receptors, serotonin 5-HT2A and 5-HT2C are class A GPCRs and 
consist of seven transmembrane helices with one intracellular amphipathic helix 8 in the C-
terminus. Both serotonin 5-HT2A and 5-HT2C receptors are densely distributed in cortex, 
however 5-HT2C receptors are in addition found in limbic regions such as the hippocampus 
and striatum. The connection between serotonin and dopamine was explained in detail in 
previous chapters. Though other neurotransmitters like GABA and glutamate are involved, 
here we are narrowing it down to only concern dopamine and serotonin.  In contrast to 
dopamine D2 receptors, serotonin 5-HT2A/5-HT2C receptors are coupled to the Gq-protein and 
PI-PLC pathway. This pathway stimulates a cascade of events involving secondary 
messengers DAG and IP3 which in turn activates protein kinase C and calcium release (11, 
71). An overview table showing the classification and subtypes of the serotonin receptor is 
added in the supplementary material. 
A relatively new atypical antipsychotic agent that was approved by FDA in 2016 called 
pimavanserin, acts as a selective antagonist/inverse agonist at the serotonin 5-HT2A receptor 
which is distinct compared to conventional antipsychotic drugs. Currently it is only approved 
for treatment of Parkinson’s disease psychosis and was proved to be well tolerated as 
monotherapy providing significant evidence for the relevance of 5-HT2A and 5-HT2C 
receptors in the treatment of psychotic symptoms. 
It was pointed out in Kimura et al 2019 (44) that one of the most important features in the 5-
HT2A receptors include a side-extended cavity near the orthosteric site where antagonists 
selectively bind. This is located between TM4 and TM5 and adjacent to Asp155(3.32) which 
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is a strictly conserved residue essential for the interactions with ligands. In the 5-HT2C 
receptor, this equals to Asp134(3.32). A hydrophobic cleft in the bottom of the ligand-binding 
pocket made up of highly conserved aromatic and hydrophobic amino acids like 
isoleucine(3.40), phenylalanine(5.47) and tryptophan(6.48), is another important feature that 
both the 5-HT2A and 5-HT2C exhibit.  Correspondingly to the important features of the 
binding of drugs to the dopamine D2 receptor, the protonated amine on pimavanserin establish 
a salt bridge with Asp155(3.32) in the serotonin 5-HT2A receptor in addition to hydrophobic 
interactions with a hydrophobic cluster made up of Phe243(5.47), Phe332(6.44), 
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1.8 Computational methods   
 
Computational methods and molecular modelling are terms used interchangeably and are a 
collection of various computer-based techniques applied for representation and manipulation 
of three-dimensional structures to relate them to their biological activity (31). Hence, these 
scientific methods are used to create logical assumptions that can be demonstrated in 
mathematical equations to facilitate reasonable predictions. Examples of some computational 
methods include virtual screening, induced fit docking (IFD) and molecular dynamic (MD) 
simulations. Applied in drug discovery, computational methods like IFD and especially MD 
simulations, have indeed proven to accelerate and reduce the immense cost, risk and time it 
takes to develop a new drug (72). In this thesis, these methods are utilized to examine 
interactions between antipsychotic drugs and the D2 and 5-HT2A receptors.  
 
1.8.1 Induced fit docking and scoring 
 
Induced fit docking (IFD) was one of the two computational methods that were most relevant 
in this project. In standard docking studies, ligands are placed or docked into binding sites of 
rigid receptors while the ligand itself moves freely. However, using static structures can lead 
to incomplete information especially since GPCRs are highly flexible and undergo dynamic 
changes upon ligand binding. Therefore, the main application of IFD was generating accurate 
complex structures for ligands that are antipsychotic drugs. Such methods allowed the 
receptor or target molecule to alter its conformation and shape of e.g., the binding site to 
better accommodate the ligand. Thus, producing all possible conformations (also referred to 
as poses) of the protein-ligand complexes that resemble biological systems. The scoring step 
in this process calculates the theoretical binding energy or affinities between the ligand and 
the target and further provides a docking score value for each of the poses which can be 
ranked from low to high (73). The binding energy, also known as Gibbs free energy (ΔG) is 
composed of enthalpic (ΔH) and entropic (ΔS) contributions summarized in following 
equation: ΔG = ΔH- TΔS where T stands for temperature in kelvin.  
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1.8.2 Molecular dynamics simulations 
 
The other computational method used was molecular dynamic (MD) simulations. MD 
simulations were applied to explore and account for macroscopic properties of several 
systems through calculation of energies, geometry, ligand binding, creating minimized 
structures and conformations. The main advantage with MD simulations is that it provides the 
means to very accurately solve equations of dynamic particles and capture the behaviours of 
biological systems over time in full atomistic detail with high resolution (72, 74). Further, it 
provides an insight into mechanisms and processes that would be time consuming, costly and 
complicated to investigate using traditional laboratory experimental studies. However, 
applying this method does not replace the need for traditional in vitro experiments in the 
laboratory, but it tremendously improves and simplifies the process.     
 
1.8.3 Energy minimalization and force field 
 
When utilizing computational methods, it is desired to find the arrangement of the ligand in 
the binding site with the lowest energy, hence the conformation with minimal energy strain. 
This process is called energy minimalization and helps to find the most stable conformation 
of the protein-ligand complex because it happens that during the construction process of the 
complex that i.e., steric hindrance, clashes, unfavourable bond angles and length arise (31). 
This will have a huge negative impact on the overall energy of the entire system. Following 
an energy minimalization, all unfavourable bonds are altered, and the system become more 
energetically stable (74).  
For both the induced fit docking, scoring and the MD simulations, force fields were used to 
estimate the interacting energy between atoms and molecules in addition to calculating the 
potential energy of the systems. Force fields are used to describe the interactions within a 
molecule (intramolecular interactions) and the interactions that occur between molecules such 
as a ligand and its target (intermolecular interactions) (75). They consist of a set of potential 
energy formulas that include parameters that take both bonded, covalent atomic interactions, 
angle bending, bond stretching and nonbonded (non-covalent), van der Waals, electrostatic 
and hydrogen bonding interactions into account (76).  
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2 Aim 
 
The Norwegian prescription database (77) revealed that a total of 131000 patients in all age 
groups and both genders had dispensed antipsychotic medications from Norwegian 
pharmacies in 2019. By roughly estimation in a population consisting of approximately 
5,000,000 inhabitants, close to 3% of the Norwegian population had prescription on 
antipsychotic medications this year.  The most commonly prescribed antipsychotics according 
to the prescription database, included levomepromazine, prochlorperazine, quetiapine, 
olanzapine, aripiprazole and risperidone. Further, pimavanserin (currently only available in 
USA) is the only non-dopaminergic antipsychotic as it performs its action through selective 
antagonism on the serotonin 5-HT2A receptor. The previously mentioned antipsychotics on the 
other hand, exert their actions through antagonism mainly on the dopamine D2 receptor, but 
also on the serotonin 5-HT2A receptor.  
The aim of this study is therefore to understand the structural mechanisms for which the most 
commonly prescribed antipsychotics act by and also get a deeper insight into putative 
structural mechanism that may explain how and why many patients experience certain serious 
adverse effects upon use. Interactions between ligands and respective targets are being 
investigated to comprehend how the desired effect is achieved but also to understand how the 
undesired adverse effects like sedation, weight gain, hormonal disturbance and motor 
dysfunction occurs. Additional aims included achieving more comprehensive understanding 
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3 Methods 
 
3.1 Software package 
3.1.1 Schrödinger Maestro (release 2021-1) 
Computational methods were utilized to investigate protein-ligand interactions and perform 
molecular dynamic calculations. The software package that was used was Schrödinger 
Maestro (Schrödinger release 2021-1) which is the graphical user interface and includes 
several programs that were used to create the antipsychotics drug, prepare the drugs 
(LigPrep), prepare the protein structures (Protein Preparation Wizard) and dock the drugs 
(Induced Fit Docking) into binding sites in structures of biogenic amine receptors. 
Additionally, Desmond (Schrödinger release 2021-1) from the same software was used to run 
high-performance molecular dynamic simulations. 
 
3.2 Databases 
3.2.1 The Protein Data bank 
The protein structures of the receptors were retrieved from the Protein Data Bank (PDB) 
which is a resource that provides information about the three-dimensional shapes of proteins 
(78). The respective files from PDB were 6VMS (69) – structure of dopamine D2 receptor G-
protein complex in a lipid membrane with the agonist bromocriptine, 6CM4 (79) - structure 
of dopamine D2 receptor bound to antagonist risperidone, 3RZE (80)- human histamine H1 
receptor in complex with antagonist doxepin, 6A93 (81) - serotonin 5-HT2A receptor in 
complex with antagonist risperidone and lastly 6BQH (82) - serotonin 5-HT2C receptor in 
complex with the antagonist ritanserin. There was no need of homology models due to the 
fact that all protein structures of interest, were already solved and accessible in the Protein 
Data Bank. The datafiles from PDB for 6CM4, 3RZE,6BQH and 6A93 have been solved 
using x-ray crystallography and had resolutions on 2.87 Å, 3.10 Å, 2.70 Å and 3.00 Å 
respectively. 6VMS on the other hand, was solved with cryo electron microscopy with 3.80 Å 
in resolution.  
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3.2.2 Orientations of Proteins in Membranes 
OPM, Orientations of Proteins in Membranes, is a database that was used to optimize the 
spatial arrangement of the receptor transmembranes in lipid bilayers based on the PDB files 
(83). In the present study, the files that were downloaded from this database included 6VMS, 
6CM4 and 6A93.  
 
3.2.3 Psychoactive Drug Screening Programme 
Another useful database was The PDSP (Psychoactive Drug Screening Programme) Ki 
database which provided information about antipsychotic drugs and their published binding 
affinities (Ki value) on different target molecules such as GPCRs (84). The Ki values for all 37 
antipsychotic drugs that were docked, were obtained from The PDSP Ki database with some 
exceptions as explained in later chapters. Finally, computational methods in the form of IFD 
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3.3 Induced Fit Docking 
 
First step in the process was to set up the three-dimensional (3D) structures of the drugs. The 
structures of 37 established antipsychotic drugs (approved for treatment of psychosis and 
pimavanserin approved for treatment of psychosis in patients with Parkinson’s disease in U.S) 
were created in Maestro based on their SMILES codes and further prepared using the ligand 
preparation module LigpPrep (Schrödinger release 2021-1). The following antipsychotic 
drugs were created: Fluphenazine, Risperidone, Paliperidone, Pimozide, Amisulpride, 
Brexpiprazole, Sulpiride, Ziprasidone, Sertindole, Haloperidole, Droperidole, Iloperidone, 
Pimavanserin, Perospirone, Zuclopenthioxol, Zotepine, Lurasidone, Mesoridazine, 
Cariprazine, Asenapine, Pipotiazine, Chlorprothiexene, Flupentixole, Thioridazine, 
Chlorpromazine, Thiothiexene, Aripiprazole, Prochlorperazine, Perphenazine, Clozapine, 
Quetiapine, Levomepromazine, Loxapine, Olanzapine, Trifluoperzine and Cyamemazine. 
The two-dimensional (2D) structures of the drugs are presented in figure 8. After running this 
preparation in physiological pH 7.0 +/- 2.0, all drugs gained a positive charge that was crucial 
for interaction with an aspartic acid residue in transmembrane helix 3, Asp(3.32) that is 
conserved among biogenic amine receptors. This application generated low-energy 3D 
structures of the antipsychotics based on their 2D structure with correct chirality, 
conformations, stereochemistry and ionization state. The force field used to estimate the 
forces and prepare the ligands in IFD was OPLS3e which stands for optimized potentials for 
































Figure 8: two-dimensional (2D) chemical structures of the 37 antipsychotic drugs docked 
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3.3.1 Protein preparation and induced fit docking calculations 
 
All 37 established drugs were docked using induced fit docking (IFD) based on the IFD 
protocol (86). IFD was implemented to accurately fit and predict most favourable 
conformation of ligand-protein complex. The receptors were run through protein preparation 
wizard (Schrödinger release 2021-1) (87) with the purpose of locating and fixing structural 
defects in the imported protein structure and thereby preparing them for use. This included 
adding missing loops and hydrogen atoms, correcting charge states and conformations. The 
workspace was then analysed and unnecessary molecules such as cholesterol, palmitic acid, 
pentaethylene glycol, oleic acid and dihydroxyethylether were removed from the protein 
structures.  
To make sure that all poses/conformations had the most desired interactions (i.e., those 
involving protonated amino group in drug and an Asp residue in transmembrane helix 3, 
(Asp3.32), constraints were used to run the IFD. The exact constraints that were used, are 
shown in figure 1 in the supplementary material. In addition to the constraints, a grid was 
generated to specify the binding site by choosing the aspartic acid (3.32) in transmembrane 
helix 3 of the receptor as the centre and the docking box. In order to be able to identify 
corresponding residues across class A GPCRs, position identifiers have been used according 
to the Ballesteros-Weinstein numbering scheme (58). According to this numbering scheme, 
residues within the TM helices are numbered relative to the most highly conserved residue 
within each residue that is given the number 50. The first number denotes the helix (1-7) 
while the second number indicates its position relative to the most conserved position in that 
helix. In Asp(3.32), this means that the residue is located in TM3, 18 positions N-terminal of 
the most conserved residue. In all GPCRs within class A, the position identification is the 
same while the receptor sequences vary. Asp(3.32) equals to Asp114 in the dopamine D2 
receptor and Asp155 in the serotonin 5-HT2A receptor.  
The maximum box size used for docking was 20 angstroms in each direction (20 Å3). The 
advantage of using IFD compared to conventional glide docking is that IFD provides both 
ligand and protein flexibility and is thus more realistic. The best poses, those that were 
energetically favourable, were chosen based on mainly docking scores. Lastly, the induced fit 
docking processes were run on 12 central processing units (CPU´s).  
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3.4 Molecular Dynamics simulation 
 
MD simulations were performed to analyse the physical motions of drugs and receptors at 
atomistic and molecular levels, but also gain detailed information about fluctuations. In short, 
MD simulations were used to investigate the structure and dynamical behaviours in biological 
environments. This computational method was used to properly understand how different 
types of antipsychotic drugs interact with several amine receptors by inducing conformational 
changes into the receptor structure during MD simulations. Bromocriptine - a D2 agonist, 
risperidone - a D2 antagonist, aripiprazole - a D2 partial agonist and pimavanserin – a 5-HT2A 
antagonist were used to compare how their mechanisms of actions affect the structure of the 
dopamine D2 and serotonin 5-HT2A receptors. Since there were no PDB files for pimavanserin 
in the serotonin 5-HT2A receptor, pimavanserin was docked into this receptor structure using 
PDB file of the 5-HT2A (PDB: 6A93), after removing risperidone. Besides the mentioned 
ligand-bound complexes, three ligand-free systems were constructed to further study and 
compare the influence of the ligands on the dynamic profiles (structural motions) of the 
receptors. This was done by removing the ligand from the D2 agonist protein (PDB: 6VMS), 
D2 antagonist protein (PDB: 6CM4) and 5-HT2A antagonist protein (PDB: 6A93).  
MD simulations of the systems were performed using the 2020-4 release of the Desmond 
module in the Schrödinger software. To successfully run the simulations, the Desmond 
protocol (75) was implemented and run on a single graphics processor (GPU).  
 
3.4.1 Constructing the systems  
 
The PDB file 6VMS (69) – structure of dopamine D2 receptor G-protein complex in a lipid 
membrane with bromocriptine was used as a starting point because the ligand bromocriptine 
was already bound to the system in addition to a G-protein complex.  The system consisted of 
chain A (guanine nucleotide-binding protein Gi subunit alpha-1), chain B (guanine 
nucleotide-binding protein Gi/Gs/Gt subunit beta-1), chain C (guanine nucleotide-binding 
protein Gi/Gs/Go subunit gamma-2), chain E (svFv16 single chain antibody) and chain R 
(dopamine D2 receptor). During protein preparation chain E was removed since the antibody 
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is only present to stabilize the receptor structure during crystallization without interfering 
with ligand binding.  
Before running the MD simulations, all systems were prepared with the protein preparation 
wizard like described in earlier sections. After preprocessing, unnecessary molecules such as 
cholesterol, palmitic acid, pentaethylene glycol, oleic acid and dihydroxyethylether were 
removed from the protein structures and only ligand remained. However, when preparing the 
dopamine D2 receptor for MD with risperidone without the G-protein (PDB: 6CM4), there 
were still missing loops in the structure after running the protein preparation, that manually 
had to be corrected. This was done by implementing the crosslinker protein panel (88). 
Utilizing this panel, it was assumed that the missing loops were not included in the sequence 
(because it failed to fill in the missing loops with protein preparation wizard several times) so 
that the “loose ends” could be cross-linked. This was quickly performed by defining the 
attachment points on both ends of the structure, defining the monomer set and multi-residue 
set of the linker. Following this process, the residues were refined and the whole system 
minimized before running MD simulation on the finished structure. In this part of the study, 
no constraints were used.  
After running MD simulation with bromoergocriptine in the active site, bromocriptine was 
removed for aripiprazole to be docked with IFD in the same protein structure. The pose with 
the best docking score was chosen for MD simulations. MD simulations were run for 
risperidone with PDB file 6CM4 (structure of dopamine D2 receptor bound to antagonist 
risperidone) without the G-protein complex on the receptor protein. There was no need to 
perform an IFD prior to the MD because risperidone was already bound to the dopamine D2 
receptor. However, protein preparation wizard was run as usual before starting MD 
simulations. Pimavanserin was docked into the serotonin 5-HT2A receptor (PDB: 6VMS) and 
the pose with the best docking score was selected for MD. This pose had a docking score of – 
11.40 kcal/mol.  
In each turn, all the ligand-bound systems were merged with a palmitoyl-oleoyl-
phosphatidylcholine (POPC) membrane bilayer environment, based on Orientations of 
Proteins in Membranes server, OPM (83). The OPM provided structural and spatial 
arrangements of membrane proteins with respect to the lipid bilayer. The solvent model that 
was used in all systems was SPC which stands for simple point-charge. SPC solvent model is 
an empirical model where water molecules are modelled as rigid triangles with charges 
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distributed over all atoms and is thus among the simplest water models utilized in molecular 
dynamic simulations (89).  
After downloading the PDB files with correct orientation via OPM, a FASTA file from 
UniprotKB database (90) was also incorporated to ensure the right structure for dopamine D2 
receptor. The FASTA file included the amino acid sequence of the human dopamine D2 
receptor and had the code P14416. In the case where the OPM was not specific enough to 
place the membrane, for instance when preparing the serotonin system, the membrane was 
manually added by selecting the residues within all seven TMs and finally placing it. Further, 
the embedded systems were neutralized with salt solutions of 0.15 M NaCl. The boundary 
conditions were set to an orthorhombic box shape with the edges of the box 10 Å away from 
the protein ligand-complex in all directions. The overall number of atoms in the 
bromocriptine and aripiprazole systems including the G-protein, water molecules, ions and 
POPC was approximately 138000 each. Figure 9 displays the whole bromocriptine – D2 + Gi 
complex. For the risperidone system without a G-protein and serotonin 5-HT2A receptor – 
pimavanserin complex, including water molecules, ions and POPC, the total numbers of 
atoms was 38000 and 46500 respectively.  
Before running the MD simulations, all of the systems were gradually relaxed through 
equilibration and minimization using the default protocols of Desmond. Interactions between 
atoms were calculated with the OPLS_2005 force field. The isothermal-isobaric ensemble 
NPT maintained a constant temperature at 300 K and pressure at 1.01325 bar during the 
simulations. 1000 ns long atomistic MD simulations with a recording interval of 250 ps were 
run for seven systems (four ligand-bound and three ligand-free) and provided 4000 frames 
each. An additional MD simulation was run for bromocriptine in dopamine D2 receptor 
without the G-protein over a period of 100 ns with a recording interval of 100 ps for later 
comparisons. Ultimately, the trajectory frames from the MD simulations were used to process 
and analyse the simulation results.   
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Figure 9: bromocriptine – D2 + Gi including the G-protein (large green unit below the membrane, CPK model), 
water molecules and ions (chloride (Cl-) ions as purple spheres, Na+ ions blue spheres, CPK model) and POPC 
(membrane displayed in grey). The D2 receptor is embedded within the membrane and TM helices are shown as 
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4 Results 
4.1 Induced fit docking 
 
All of the 37 ligands were docked into the orthosteric binding site domain of the four receptor 
structures dopamine D2, serotonin 5-HT2A, 5-HT2C and histamine H1 receptor using the 
Schrödinger IFD protocol (schrödinger release 2021-1). The results from the IFD scoring 
values, their intrinsic activity and inhibition constants for the four receptors, are presented in 
tables 1- 4. Only the lowest energy IFD scores were selected and matched up with affinity 
values, Ki, from the PDSP database (84). The affinities for levomepromazine, asenapine, 
pimavanserin and paliperidone on these receptors were not available in the database so they 
were retrieved from their supplementary protection certificates; asenapine (91) and 
pimavanserin (92) and previous articles, levomepromazine (93) and paliperidone from 
McLeod 2015 (94). No affinity data was found for some of the ligands and therefore left 
blank with a hyphen.  
 As a rule of thumb, the lower the Ki, the greater the binding affinity. A low Ki indicates 
greater ability for a ligand to bind to its target. High affinity ligands require lower 
concentrations to produce desired effect (95). To systematically classify the ligands based on 
affinity, the Ki values were rated on a four-point scale according to Yonemura et.al 1998 (93). 
Ligands with Ki values on the order of 1nM or less were defined as high affinity. Ki values on 
the 10 nM order, meaning under 100 nM was categorized as moderate affinity while ligands 
with Ki values on 100 nM order were relatively low affinity. Finally, low affinity ligands were 
those with values over 1000 nM. Regarding the docking scores, generally they are only 
describing favourable binding or orientation of a ligand in the target but alone does not serve 
as useful surrogates for binding affinity. Nevertheless, the general interpretation of docking 
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Table 1 – Dopamine D2 receptor binding affinity (Ki) and IFD docking score corresponding to the best docking 
pose for antipsychotic drugs.   
Ligands Intrinsic activity Ki (nM) IFD score 
(kcal/mol) 
 
Amisulpride Antagonist 3.0 -8.4  
Aripiprazole Partial agonist 0.3-0.9 -8.8  
Asenapine Antagonist  1.3 -8.4  
Brexpiprazole Partial agonist  0.2 -10.7  
Cariprazine Partial agonist 0.5-0.7 -8.1  
Chlorpromazine Antagonist 7.2 -8.3  
Chlorprothixene  Antagonist 3.0-5.6 -8.6  
Clozapine Antagonist 44-330 -7.9  
Cyamemazine Antagonist  5.8 -7.4  
Droperidol Antagonist  -  -9.6  
Z-Flupentixol Antagonist 0.4 -9.9  
E-Flupentixol Antagonist 120 -8.6  
Haloperidol Antagonist  0.3-10 -9.6  
Fluphenazine Antagonist 0.2-1.4 -9.1  
Iloperidone Antagonist 0.4-21.4 -9.5  
Levomepromazine Antagonist  5.9 -6.9  
Loxapine Antagonist 5.2-71.4 -7.8  
Lurasidone Antagonist  1.7 -10.9  
Mesoridazine Antagonist 4.4-19 -8.5  
Olanzapine Antagonist  3.0-106 -7.3  
Paliperidone  Antagonist  2.5 -10.2  
Perospirone Antagonist 0.6 -10.5  










Pipotiazine Antagonist  0.2 -9.2  
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Prochlorperazine Antagonist  0.2-7.0 -8.9  
Quetiapine Antagonist  78-1000 -8.7  
Risperidone Antagonist 0.3-19 -9.8  
Sertindole Antagonist 0.6-9.1 -10.7  
Sulpiride Antagonist  4.2-206 -9.2  
Thioridazine Antagonist  0.4-26.7 -8.0  
Tiothixene Antagonist  0.03-1.4 -8.0  
Trifluoperazine  Antagonist -  -7.9  
Ziprasidone Antagonist  0.8-9.7 -9.8  
Zotepine Antagonist 5.4-11 -9.5  




Table 2 – Serotonin 5-HT2A receptor binding affinity (Ki) and IFD docking score corresponding to the best 
docking pose for antipsychotic drugs.   
Ligands  Intrinsic activity Ki (nM)  IFD score 
(kcal/mol) 
 
Amisulpride Antagonist  8.3 -9.2  
Aripiprazole Partial agonist  3.4-35 -9.7  
Asenapine Antagonist 0.06 -9.6  
Brexpiprazole Antagonist   0.5 -11.2  
Cariprazine Antagonist   18.8 -8.5  
Chlorpromazine Inverse agonist  2.8 -9.0  
Chlorprothixene Antagonist  0.3-0.4 -9.4  
Clozapine Inverse agonist  5.4 -9.8  
Cyamemazine Antagonist 1.5 -10.4  
Droperidol -  -  -9.5  
Z-Flupentixol Antagonist  87.5 -10.9  
Main source: PDSP Ki database 
No data – marked with hyphen (-) 
Some drugs have varying Ki values (based on different sources) and are therefore listed as intervals 
 
 
Page 52 of 116 
E-Flupentixol Antagonist  -  -10.8  
Haloperidol Antagonist  25-120 -10.5  
Fluphenazine Antagonist  3.2 -9.6  
Iloperidone Antagonist  0.1-5.6 -9.8  
Levomepromazine Antagonist  0.07 -9.5  
Loxapine Inverse agonist 1.7-13.5 -8.7  
Lurasidone Antagonist  2.0 -11.3  
Mesoridazine Antagonist  4.8-11.7 -11.4  
Olanzapine Antagonist  1.5-24 -8.9  
Paliperidone  Antagonist  1.2 -11.2  
Perospirone Antagonist  1.3 -10.0  










Pipotiazine Antagonist  -  -11.31  
Prochlorperazine -  7.2-15 -9.0  
Quetiapine Antagonist 31-2500 -8.6  
Risperidone Inverse agonist  0.1-7.0 -9.8  
Sertindole Antagonist  0.3-6.0 -11.2  
Sulpiride -  4.8 -8.9  
Thioridazine Antagonist  1.1-60.0 -10.5  
Tiothixene Antagonist 50.0 -9.7  
Trifluoperazine  Antagonist  -  -9.5  
Ziprasidone Antagonist  0.08-1.7 -8.9  
Zotepine Antagonist  2.6 -10.4  
Zuclopenthixol Antagonist  -  -10.8  
 
 
Main source: PDSP Ki database 
No data – marked with hyphen (-) 
Some drugs have varying Ki values (based on different sources) and are therefore listed as intervals 
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Table 3 – Serotonin 5-HT2C receptor binding affinity (Ki) and IFD docking score corresponding to the best 
docking pose for antipsychotic drugs 
Ligands       Intrinsic activity Ki (nM) IFD score 
(kcal/mol) 
Amisulpride -  >10000    -7.7 
Aripiprazole Partial agonist  15-180 -9.1 
Asenapine Antagonist  0.03 -8.8 
Brexpiprazole Partial agonist    12-34 -9.2 
Cariprazine Inverse agonist  134 -8.3 
Chlorpromazine Antagonist  25 -9.0 
Chlorprothixene Antagonist  4.5 -9.3 
Clozapine Inverse agonist  9.4 -9.5 
Cyamemazine Antagonist 12 -8.4 
Droperidol -  -  -9.4 
Z-Flupentixol -  102.2* -10.3 
E-Flupentixol -  -  -10.7 
Haloperidol Antagonist  >10000 -9.6 
Fluphenazine Antagonist  174-2570 -10.1 
Iloperidone Antagonist  14-251 -9.1 
Levomepromazine Antagonist  0.07 -8.9 
Loxapine Inverse agonist 9.5 -9.1 
Lurasidone -  415* -11.3 
Mesoridazine Antagonist  157 -10.5 
Olanzapine Inverse agonist   4.1-71 -9.3 
Paliperidone  Antagonist  48 -10.7 
Perospirone -  -  -10.2 
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Pipotiazine -  -  -10.9 
Prochlorperazine -  122 -9.1 
Quetiapine Antagonist  615-3500 -9.5 
Risperidone Inverse agonist   10.0-64.0 -9.1 
Sertindole Inverse agonist   0.3-6.0 -11.5 
Sulpiride -  -  -7.4 
Thioridazine Antagonist  53.0 -10.4 
Tiothixene -  1350 -8.7 
Trifluoperazine  Antagonist  -  -9.7 
Ziprasidone Inverse agonist   0.7-13.0 -9.0 
Zotepine Inverse agonist   3.2 -10.4 




Table 4 – Histamine H1 receptor binding affinity (Ki) and IFD docking score corresponding to the best docking 
pose for antipsychotic drugs 
Ligands  Intrinsic 
activity 
 Ki (nM) IFD score 
(kcal/mol) 
Amisulpride -   >10000 -9.6 
Aripiprazole Antagonist   25.1-61 -9.6 
Asenapine Antagonist   1.0 -8.9 
Brexpiprazole Antagonist   19.0 -11.0 
Cariprazine Antagonist     23.2 -8.5 
Chlorpromazine Antagonist   4.25 -9.7 
Chlorprothixene Antagonist  0.9-3.8 -8.7 
Clozapine Antagonist   1.1 -8.9 
Cyamemazine Antagonist   9.3* -9.3 
Droperidol -   -  -10.7 
Main source: PDSP Ki database 
No data – marked with hyphen (-) 
Species measured on deviates from human – marked with asterix (*) Lurasidone = pig, Z-flupentixol = rat  
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Z-Flupentixol -   0.9 -11.7 
E-Flupentixole -   5.7 -12.5 
Haloperidol Antagonist   1800 -9.7 
Fluphenazine Antagonist   7.3-70 -12.5 
Iloperidone -   12.3 -10.1 
Levomepromazine Antagonist   0.6 -8.4 
Loxapine Antagonist   2.2-3981 -7.6 
Lurasidone -   >1000* -10.8 
Mesoridazine Antagonist   1.8 -12.0 
Olanzapine Antagonist   0.09-4.9 -9.8 
Paliperidone  Antagonist   -  -11.5 
Perospirone -   -  -11.4 













Prochlorperazine Antagonist   6.0-19.0 -11.3 
Quetiapine Antagonist   2.2-12.9 -10.8 
Risperidone Inverse agonist  3.5 -9.5 
Sertindole Antagonist   130.0 -12.7 
Sulpiride -   72443 -9.4 
Thioridazine Antagonist   2.5-17.0 -9.9 
Tiothixene Antagonist  4.0-12.0 -11.9 
Trifluoperazine  Antagonist   -  -11.0 
Ziprasidone Antagonist   4.6-47.0 -9.9 
Zotepine Antagonist   0.6-5.8  -10.8 
Zuclopenthixol Antagonist  -  -10.9 
 
Main source: PDSP Ki database 
No data – marked with hyphen (-)  
Species measured on deviates from human – marked with asterix (*) Lurasidone and Cyamemazine = guniea pig 
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4.1.1 Binding affinity Ki and docking scores 
 
Levomepromazine, prochlorperazine, quetiapine, olanzapine, risperidone and aripiprazole are 
the most prescribed antipsychotic drugs in Norway based on the Norwegian prescription 
database. On that account, they will be exclusively pointed out even though there are drugs in 
the tables with “better” affinity values and docking scores. These numbers alone do not 
predict how effective the agents are, nor if they actually are on the marked for use under the 
indication of being antipsychotic. The affinity of levomepromazine, prochlorperazine, 
olanzapine, aripiprazole and risperidone on the dopamine D2 receptor was high as their Ki 
values were on the order of 1 nM and ranged from 0.2 nM to 5.9 nM. Quetiapine on the other 
hand, recorded moderate affinity because the lowest reported Ki value was 78 nM on the 
dopamine D2 receptor. Of the 37 docked drugs, none could be classified as low affinity drugs 
on the dopamine D2 receptor because their Ki values were all below 1000 nM.  
In addition to looking at levomepromazine, prochlorperazine, quetiapine, olanzapine, 
risperidone and aripiprazole, investigating pimavanserin is of interest especially since it is the 
only antipsychotic drug known that does not interact with the dopamine D2 receptor as an 
antagonist or partial agonist.  On the serotonin 5-HT2A receptor, levomepromazine, 
prochlorperazine, quetiapine, olanzapine, risperidone and aripiprazole had Ki values on 0.07 
nM, 7.2 nM, 31 nM, 1.5 nM, 0.1 nM and 3.4 nM respectively which rate them high to 
moderate affinity. Pimavanserin had no reported value on the dopamine D2 receptor but had 
very high affinity on the serotonin 5-HT2A receptor with a Ki value of 0.09 nM. Other drugs 
that showed high affinities on this receptor, were chlorprothixene, sertindole and ziprasidone 
with affinity values ranging between 0.08 – 6.0 nM.  
High affinity for the serotonin 5-HT2C receptor was registered for levomepromazine, 
olanzapine and pimavanserin with affinity values of 0.07 nM, 4.1 nM and 0.44 nM 
respectively. The lowest reported Ki value for risperidone was 10 nM and 15 nM for 
aripiprazole which rendered them as moderate affinity drugs on the 5-HT2C receptor. 
Relatively low affinity, with Ki values on the order of 100 nM, was shown by 
prochlorperazine and quetiapine. The Ki values of these drugs were 122 nM for 
prochlorperazine and 615 nM for quetiapine. Among the drugs that exhibited low affinity for 
5-HT2C receptor, were amisulpride and haloperidol, both with Ki values over 1000 nM.  
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The affinity of the selected drugs (levomepromazine, olanzapine, prochlorperazine, 
quetiapine, aripiprazole and risperidone) for the histamine H1 receptor was high to moderate 
with Ki values ranging from 0.09 – 25.1 nM. Sertindole was the only drug that had relatively 
low affinity for the H1 receptor with a Ki value of 130 nM. Out of all 37 drugs, olanzapine 
had the highest affinity with 0.09 nM while lowest affinity was seen for sulpiride with a Ki 
value of 72443 nM.   
Concerning the docking scores, pimavanserin had -9.5 kcal/mol on the dopamine D2 receptor 
and -11.4 and -10.2 kcal/mol on the serotonin 5-HT2A and 5-HT2C receptors respectively. The 
docking scores for aripiprazole were -8.8, -9.7, -9.1 and -9.6 kcal/mol on the dopamine D2, 
serotonin 5-HT2A, 5-HT2C and histamine H1 receptors respectively. Conclusively, all of the 
selected drugs had good docking scores on all receptors as seen in the tables. Some of the 
drugs that stood out with extremely good scores below -10 kcal/mol on the histamine H1 
receptor were brexpiprazole, Z and E-flupentixol, fluphenazine, lurasidone and sertindole. 
Their docking scores were -11.0 kcal/mol for brexpiprazole, -11.7 kcal/mol for Z-flupentixol, 
-12.5 kcal/mol for E-flupentixol and fluphenazine, -12.5 kcal/mol for lurasidone and -12.7 
kcal/mol for sertindole. The docking score of pimozide was the highest on the dopamine D2 
receptor with a value of -13.2 kcal/mol while the reported Ki values for pimozide ranged 
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4.2 Molecular dynamics simulations 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
Three ligand-free complexes were constructed in addition to the four ligand-bound complexes 
to better understand the influence of ligand binding on the proteins. These were, dopamine D2 
receptor including G-protein without a ligand, dopamine D2 receptor without G-protein or a 
ligand and lastly serotonin 5-HT2A receptor without a ligand. The ligand-bound complexes 
were bromocriptine and aripiprazole bound to the dopamine D2 receptor including G-protein, 
risperidone bound to dopamine D2 receptor without G-protein and pimavanserin bound to 
serotonin 5-HT2A receptor.  
 
4.2.1 Structural stability analysis  
 
The stability of the protein in complex with ligands relative to its conformation was 
determined by the deviations from the starting structures, produced during the 1000 ns long 
MD simulations. Principally, the smaller the deviations the more stable the protein structure. 
In the present thesis, the root mean square deviation (RMSD) and root mean square 
fluctuation (RMSF) for the backbone atoms were measured. RMSD measured the average 
difference between the backbone atoms of the respective proteins from its initial structural 
conformation to the final position by superimposing all frames on the reference frame over 
the course of the simulation. RMSF on the other hand, was measured to characterize the 
degree of fluctuation of the residues in the receptors in complex with the different ligands. 
Additionally, secondary structure elements like 𝛼-helices and 𝛽-strands are displayed in the 
figures. 𝛼-helical and 𝛽-strand regions are highlighted in red and blue backgrounds 
respectively.  
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4.2.1.1 Root mean square deviation  
 
RMSD value for the backbone was measured for all MD simulations that were run in order to 
study the stability of the simulations. The evolution plots from the MD simulations for 
bromocriptine, aripiprazole, risperidone and pimavanserin with average and maximum RMSD 
values are profiled in figure 10. The protein structure systems for 1000 ns simulations of 
bromocriptine and aripiprazole included the dopamine D2 receptor plus G-protein, while the 
risperidone system only included the dopamine D2 receptor. The 100 ns long MD simulation 
of bromocriptine was without the G-protein. RMSD for the pimavanserin system was 
calculated on the serotonin 5-HT2A receptor (without G-protein as well). Three ligand-free 
simulations were also run, the first one being dopamine D2 receptor including G-protein, the 













Figure 10: RMSD plots of backbone atoms for bromocriptine, aripiprazole, risperidone and pimavanserin. 
Maximum RMSD values were calculated after superimposing frame 849,3780, 3780 and 3524 (highest peaks) on 
the starting structure respectively.  
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For the bromocriptine – receptor complex, the highest observed RMSD value was 7.41 Å 
approximately 200 ns into the simulation as the system had a slight increasing trend in the 
beginning. Approaching 250 – 300 ns into the simulation, the system equilibrated at around 
4.66 Å for the remaining course of the simulation. Interestingly, the aripiprazole–receptor 
complex never seemed to fully equilibrate and the highest noticed RMSD was 9.52 Å towards 
the end of the simulation. Nonetheless, the mean RMSD was 6.59 Å. The curve for the 
ligand-free dopamine D2 receptor including G-protein system (figure 11), appeared to slowly 
increase in a straight pathway during the simulation with the highest RMSD value calculated 
at 12.01 Å 9.15 Å at average.  
Maximum and average RMSD values for the risperidone system was 4.57 Å and 3.47 Å 
respectively. The conformational deviation from the initial structure appears to harmonically 
change in an increasing manner. Judging from the previously mentioned RMSD analysis, 
pimavanserin in the 5-HT2A receptor with mean and highest RMSD values 3.95 Å and 5.46 Å 
respectively, represents the most stable conformers among the simulations. It increases at the 
onset up to 200 ns before it maintains a more or less straight path with a few peaks out the 
simulation. The highest observed peak was measured at 5.18 Å. The measured RMSD values 
for ligand-free system number two, D2 without G-protein, were 3.85 Å at mean and 5.27 Å at 
maximum. For ligand-free system number three, 5-HT2A, RMSD values were 5.42 Å 
(maximum) and 3.81 Å (mean) respectively. The plots for the ligand free systems are shown 






Figure 11: RMSD plots of backbone atoms for ligand-free systems, D2 receptor with and without G-protein and 
also 5-HT2A receptor. Maximum RMSD values were calculated after superimposing the frames with the highest 
peaks on the starting structure.  
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4.2.1.2 Root mean square fluctuation  
 
RMSF analysis based on the backbone atoms were carried out along with RMSD to fully 
obtain a picture of the movement and conformational changes of the systems over the 
simulation period. The relevant plots are presented in figure 12. For both bromocriptine and 
aripiprazole in dopamine D2 receptor with G-protein, the section in the middle is coloured 
blue which indicates 𝛽-strands. These 𝛽-strands are a part of the G-protein (chain B – guanine 
nucleotide binding protein Gi, subunit 𝛽) and thus, is not found in the risperidone and 
pimavanserin systems. This region shows a relatively low and stable RMSF value of 
approximately 2.0 Å which is in good agreement with the fact that 𝛽-strands usually are rigid 
and fluctuate less compared to loop regions for instance.  
Following the 𝛽-strands section, comes an 𝛼-helical region, (after the 600-residue index 
mark), which is the 𝛼-helices of the dopamine D2 receptor. A few peaks with RMSF values of 
5.61 Å and 3.36 Å were observed in the bromocriptine system and these two peaks 
represented the amino terminals ACE (acetyl group, N-terminal) and NMA (N-methyl amide 
of C-terminal) respectively. In the aripiprazole system, more peaks were observed in the 
receptor region and highest peak to the far left had a RMSF value of 7.46 Å while RMSF 
value of the peak at the very end was 6.05 Å. Another peak was observed right after the 800-
residue index mark and RMSF value this residue, Leu222, was 6.04 Å. Besides from the 
peaks, the average RMSF values for the receptor regions were around 3.0 Å for bromocriptine 
and aripiprazole.  The RMSF plot for aripiprazole further shows more fluctuations than the 
bromocriptine curve.  
Maximum RMSF values measured for risperidone and pimavanserin were 4.21 Å for Ile394 
and 3.98 Å for Glu351 respectively. Similarly to bromocriptine and aripiprazole, the most 
fluctuating parts and highest peaks in the risperidone and pimavanserin plots are all situated 
in the loop regions (ICLs and ECLs) which are known to be more flexible than 𝛽-strands and 
𝛼-helices. For the ligand-free dopamine D2 receptor with G-protein, the highest measured 
RMSF values were 8.11 Å and 4.75 Å (ACE and NMA respectively) compared to the average 
value around 4 Å. In the plot for the D2 receptor without a G-protein, Asn35 had a RMSF 
value of 5.13 Å while the value was 5.33 Å for Asp400. Values for ACE and NMA were not 
applicable. Finally, the maximum RMSF values observed in the ligand-free 5-HT2A system 
were 8.01 Å for Thr69 and 3.88 Å for NMA (no available data for ACE).  
 































Figure 12: RMSF plots of backbone atoms for bromocriptine-, aripiprazole-, risperidone- and pimavanserin 
systems for each residue in the protein chains. RMSF value describes time-averaged fluctuation of the residues 
over the entire simulation time and is calculated after superposition on reference (starting) frame. Chain A is 
subunit 𝛼 of the G-protein, Chain B is subunit 𝛽, Chain C is subunit 𝛾 and Chain R is the dopamine D2 receptor. 
Red, blue and white fields display 𝛼-helical, 𝛽-strands and loop regions respectively.  
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Both RMSD and RMSF analysis were carried out for the 100 ns MD simulation run on 
bromocriptine without the G-protein, figure 13. Highest RMSD value observed was 3.41 Å 
while the average value was 2.79 Å. The highest peak in the RMSF plot as seen in figure 13 
was registered for ACE which had a value of 6.20 Å. The mean and NMA RMSF values were 
1.71 Å and 4.39 Å respectively. In accordance with the previous RMSF plots all peaks were 







Figure 13: Left: RMSD plot of backbone atoms for bromocriptine 100 ns MD simulation. Maximum RMSD values 
was calculated after superimposing frame 556 (highest peak) on the starting structure. Right: RMSF plot also 
based on backbone atoms. Red and white fields display 𝛼-helical  and loop regions respectively.  
  
 
4.2.2 Investigation of selected frames throughout the simulations  
 
In order to visualize the motion and dynamics of the drugs upon binding to the receptor, a 
conformational transition analysis for all systems were performed. The analysis was based on 
the MD simulation trajectory for each of the four systems, bromocriptine and aripiprazole in 
the dopamine D2 receptor including G-protein, risperidone in the dopamine D2 receptor 
without G-protein and finally, pimavanserin in the serotonin 5-HT2A receptor. Five snapshots 
were taken from the 1000 ns long simulation. The trajectory snapshots display multiple 
superimposed frames and evolution of ligand position with respect to the MD time where the 
first snapshot was captured at frame number 1. In figure 14 this is displayed in the colour 
blue. The following snapshots, frame 1001, 2001, 3001 and 4001 are coloured in lilac, white, 
beige and red respectively. A distinct deviation from the initial pose was seen for all systems 
from early in the simulation but the largest was seen for aripiprazole. The deviation was much 
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smaller for bromocriptine and risperidone when looking at the initial pose (frame 1, blue 
colour) and the final pose (frame 4001, red colour). These results were consistent with the 
findings obtained from the RMSD and RMSF analysis as the RMSD aripiprazole plot from 
figure 10 fluctuated more compared to the other plots. 
Each of the frames were studied thoroughly to investigate eventual differences in ligand-
protein contacts with respect to the dynamic receptor. However, since the frames were 
captured at five separate points during 1000 ns long simulations that generated 4000 frames, 
they are not representative for the whole simulation. Rather, they give a snapshot at the 
interactions formed at that exact time.  
 
 
Figure 14: Conformational transition analysis of agonist, antagonist and partial agonist on the dopamine D2 
receptor and antagonist on the serotonin 5-HT2A receptor (pimavanserin) during MD simulation. Colour scale is 
initiated from left to right and shows the evolution of ligand position with respect to simulation time.  
 
In frame 1, 1001, 2001 and 3001 bromocriptine created a salt bridge with Asp114(3.32) in the 
D2 receptor that was not present in frame 4001. Asp114(3.32) additionally established a 
hydrogen bond with the drug in all frames between the protonated amine group in 
bromocriptine and the carboxylate of Asp114(3.32). 𝜋 − 𝜋 stacking interactions with 
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Phe390(6.52) were present in all frames with varying numbers. Bromocriptine in frame 1, 
2001, 3001 and 4001 made two interactions with this residue while bromocriptine in frame 
1001 only made one 𝜋 − 𝜋 stacking interaction to Phe390(6.52). In addition, Phe389(6.51) 
also created a 𝜋 − 𝜋 stacking interaction with the ligand in frame 1 but not in the other 
frames. However, bromocriptine in frame 4001 established a 𝜋 − 𝜋 stacking interaction with 
His393(6.55) that was not seen in the other frames. Hydrogen bonds between both 
Ser197(5.46) and Ile184(45.52) and the ligand were present in all frames.  
Protonated amine on aripiprazole made salt bridge interactions with negatively charged 
oxygen on Asp114(3.32) in all frames. Similarly to bromocriptine, a hydrogen bond was 
formed in all frames with the carboxyl group of Asp114(3.32). Hydrogen bonds with 
Cys182(45.50) and Trp413(7.40) were present in all frames and so were 𝜋 − 𝜋 stacking 
interaction with Phe390(6.52). Interestingly, a 𝜋 − 𝜋 stacking interaction with Phe389(6.51) 
and halogen interaction between chlorine from the ligand and Ser193(5.42) were only 
observed in frame 2001.  
The ligand in all of the frames in the risperidone system made as expected, salt bridge 
interactions to Asp114(3.32). A hydrogen bond was also present in all frames between the 
protonated amine group in bromocriptine and the carboxylate of Asp114(3.32). While 
risperidone in frames 1, 3001 and 4001 engaged in two 𝜋 − 𝜋 stacking interaction with 
Trp386(6.48), the positively charged nitrogen in the ligand in frames 1001 and 2001, formed 
𝜋 − 𝑐𝑎𝑡𝑖𝑜𝑛 interaction with the same residue. A 𝜋 − 𝜋 stacking interaction with 
Phe189(5.38) was seen in frame 3001.  
Finally, for pimavanserin in the 5-HT2A receptor, apart from a salt bridge interaction and 
hydrogen bond between the ligand and carboxylate of Asp155(3.32) in all frames, two 𝜋 − 𝜋 
stacking interactions were observed with Trp336(6.48) in frame 1. No hydrophobic 
interactions seen in frame 1001. In frame 2001 one 𝜋 − 𝑐𝑎𝑡𝑖𝑜𝑛 interaction was established 
with Trp336(6.48) and a 𝜋 − 𝜋 stacking interaction with Phe234(5.38). Two 𝜋 − 𝑐𝑎𝑡𝑖𝑜𝑛 
interactions were formed with Trp336(6.48) and Phe339(6.51) in both frame 3001 and 4001. 
Conclusively, hydrogen bonds mediated through water molecules, so called water bridges, 
were present in all frames for all of the ligands but in varying amounts. It seems like 
bromocriptine and risperidone for instance, mainly had these interactions in the top of the 
binding cavity while aripiprazole and pimavanserin additionally had interactions deep in the 
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pocket. Most of the water bridges were not in direct contact with the ligand, but other residues 
that affected the overall binding profile. Figures of all frames in all systems are added in 
supplementary material figures 2-5. 
 
4.2.3 Protein-ligand interaction analysis 
 
Protein-ligand and Ligand-protein contact interaction analysis were conducted based on the 
simulation interaction diagram module (Schrödinger release 2021-1) in Desmond. These 
modules created graphical and schematic displays of the ligand interactions with various 
protein residues over the simulation period. Only interactions between ligand and receptor 
were studied, therefore it is highly possible that interactions between residues were present. 
The representative structures (average RMSD structures) of the MD trajectory frames were 
prepared for all complexes and presented as both 2D and 3D structures. Bromocriptine was 
properly accommodated in the binding cavity of the dopamine D2 receptor. The protonated 
nitrogen of the ligand formed a hydrogen bond, an ionic interaction and a water bridge with 
Asp114(3.32) in TM3 for 97%, 3.6% and 57% of the simulation time respectively. 
Ser197(5.46) contributed to a hydrogen bond as an acceptor with bromocriptine for 96% of 
the simulation. The aromatic residues Trp386(6.48), Phe389(6.51), Phe390(6.52) and 
His393(6.55), created a hydrophobic field in the binding site that had non-polar interactions 
such as vdW, 𝜋 − 𝜋 stacking and cation- 𝜋 interactions with bromocriptine for a total of 
100%. In addition, His393(6.55) and Thr412(7.39) had polar interactions with bromocriptine 
mediated by water molecules. Ile184(45.52) in ECL2 had hydrogen bond contacts as a donor 
to the ligand, in addition to water bridge and hydrophobic interactions. Apart from the 
mentioned main interactions, Phe110(3.28), Val111(3.29), Val115(3.33), Ile183(45.52), 
Phe189(5.38), Pro405 (7.32) and Tyr408 (7.35) had weak hydrophobic contacts with 





























Figure 15: Fraction of Interactions between ligand and binding site residues presented as bar-diagram. Green is 










Figure 16: Protein-ligand contact analysis of bromocriptine in dopamine D2 receptor.  In left panel: 3D 
representation of binding site residues in gray and bromocriptine in green. Dotted line in blue shows 𝜋 − 𝜋 
stacking interactions, pink dotted line shows ionic interactions, yellow line shows hydrogen bonds and red 
spheres represent water molecules. In right panel: 2D representation of binding site residues in bubbles and 
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The dopamine D2 partial agonist, Aripiprazole, also had interactions with Asp114(3.32) in the 
binding cavity. Asp114(3.32) formed strong hydrogen bond and ionic interaction with the 
positively charged nitrogen of aripiprazole for 86% and 14% of the simulation time 
respectively. Cys182(45.50) participated in two hydrogen bonds with the NH group in 
aripiprazole as a donor for 95% and as an acceptor for 97% of the time. Other critical amino 
acids involved Phe389(6.51), Phe390(6.52) and Trp413(7.40) which established hydrophobic 
𝜋 − 𝜋 stacking interaction with aripiprazole. In addition to hydrophobic interactions, 
Trp413(7.40) also contributed to a hydrogen bond with the oxygen ether group in aripiprazole 
as a donor. The amino acids Val91(5.39), Leu94(2.64), Val115(3.33), Cys118(3.36), 
Ile183(45.51) and Ile184 (45.52) engaged in less significant hydrophobic contact with 








Figure 17: Protein-ligand contact analysis of aripiprazole in dopamine D2 receptor.  In left panel: 3D 
representation of binding site residues in gray and aripiprazole in green. Dotted line in blue shows 𝜋 − 𝜋 stacking 
interactions, pink dotted line shows ionic interactions and yellow line shows hydrogen bonds. In right panel: 2D 
representation of binding site residues in bubbles and ligand in black.  
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Figure 18: Fraction of Interactions between ligand and binding site residues presented as bar-diagram. Green is 
hydrogen bonds, pink is ionic interaction, blue represents water bridges and lilac are hydrophobic interactions. 
 
The key interactions that were identified between risperidone and residues within the binding 
pocket cavity of D2 receptor involved a hydrogen bond, water bridge and ionic interaction 
with Asp114(3.32). The hydrogen bond was maintained for approximately 90% of the 
simulation time, while the salt bridge and water bridge were maintained for 12% and 3% 
respectively. The interaction analysis further suggested that Pro201(5.50), Phe202(5.51), 
Phe189(5.38), Phe382(6.44), Trp386(6.48), Phe389(6.51), Tyr408(7.35), Tyr416(7.43) and 
Trp413(7.40) established hydrophobic non-polar interactions with the ligand in the form of 
vdW, 𝜋 − 𝜋 stacking and cation- 𝜋 interactions for up to 57% of the simulation time. A 
hydrogen bond and water bridge were created between risperidone and Ser193(5.42) in 
addition to an insignificant hydrogen bond with Thr119(3.37) as seen in figure 19. A bar 

















Figure 19: Protein-ligand contact analysis of risperidone in dopamine D2 receptor.  In left panel: 3D representation of binding 
site residues in gray and risperidone in green. Dotted line in blue shows 𝜋 − 𝜋 stacking interactions, pink dotted line shows ionic 
interactions, yellow line shows hydrogen bonds and red spheres represent water molecules. In right panel: 2D representation of 









Figure 20: Fraction of Interactions between ligand and binding site residues presented as bar-diagram. Green is hydrogen 
bonds, pink is ionic interaction, blue represents water bridges and lilac are hydrophobic interactions. 
 
Pimavanserin was docked into the serotonin 5-HT2A receptor and among the main interactions 
were a hydrogen bond and a salt bridge between protonated nitrogen on ligand and 
Asp155(3.32) in binding cavity. The hydrogen bond was maintained for 94% of the 
simulation time while the ionic interaction was maintained for 6.4%. Comparably to previous 
structures, the 5-HT2A receptor has an aromatic hydrophobic network in the binding site 
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consisting of the residues Trp336(6.48), Phe339(6.51), Phe340 (6.52), Phe243(5.47) and 
Phe234(5.38) which participate in vdW, 𝜋 − 𝜋 stacking and cation- 𝜋 interactions throughout 
the simulation period. Both Asn343(6.55) and Ser239(5.43) contributed to water bridge 
interactions with the ligand for 47% and 14% of the simulation time respectively while an 
additional hydrogen bond with Ser239(5.43) was created. Ultimately, for 67% and 45% of the 
MD simulation time, a water bridge and vdW interaction respectively, were established 
between Leu229(ECL2) and pimavanserin. Visual representations in figure 21 and 22. 
Common to all systems was that none of the ligands had significant interactions with amino 











Figure 21: Protein-ligand contact analysis of pimavanserin in serotonin 5-HT2A receptor.  In left panel: 3D 
representation of binding site residues in gray and pimavanserin in green. Dotted line in blue shows 𝜋 − 𝜋 
stacking interactions, pink dotted line shows ionic interactions, yellow line shows hydrogen bonds and red 
spheres represent water molecules. In right panel: 2D representation of binding site residues in bubbles and 
ligand in black.  
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Figure 22: Fraction of Interactions between ligand and binding site residues presented as bar-diagram. Green is 
hydrogen bonds, pink is ionic interaction, blue represents water bridges and lilac are hydrophobic interactions.  
 
Bromocriptine in the shorter simulation, exhibits more or less the same interactions that were 
revealed in the bromocriptine 1000 ns with G-protein system. The main differences lie in the 
fraction of the interactions, for instance, the ionic interaction with Asp114(3.32) is established 
for approximately 11% of the simulation time, while hydrogen bond and water bridge with 
the same residue is maintained for 89% and 41% respectively. Ile184(45.52) participated in 
hydrogen bond as a donor with bromocriptine for 94% while also creating hydrophobic 
interactions. Ser197(5.46) also made a stable hydrogen bond to the ligand. Phe390(6.52), 
Phe389(6.51), His393(6.55) were making π − π stacking interactions with bromocriptine 































Figure 23: Top: Protein-ligand contact analysis of bromocriptine in dopamine D2 receptor without G-protein.  In 
left panel: 3D representation of binding site residues in gray and bromocriptine in green. Dotted line in blue shows 
𝜋 − 𝜋 stacking interactions, pink dotted line shows ionic interactions, yellow line shows hydrogen bonds and red 
spheres represent water molecules. In right panel: 2D representation of binding site residues in bubbles and 
ligand in black. Bottom: Fraction of Interactions between ligand and binding site residues presented as bar-
diagram. Green is hydrogen bonds, pink is ionic interaction, blue represents water bridges and lilac are 
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4.2.4 Comparison of active and inactive dopamine D2 receptor 
 
The conformations of inactive (bound to antagonist risperidone PDB: 6CM4) and active 
dopamine D2 receptors (bound to agonist bromocriptine PDB: 6VMS) were thoroughly 
looked at to identify the major structural differences. The most obvious differences in these 
structures that were observed, involved a rearrangement of the helices in the seven 
transmembrane domains, the most considerable being in TM3 and TM6. In figure 24, TM6 is 
coloured in dark green while TM3 is coloured in light green. In the inactive conformation, the 
cytoplasmic halves of TM3 and TM6 are oriented towards each other creating an ionic 
interaction between well conserved Arg132(3.50) and Glu368(6.30) also known as an ionic 
lock. The ionic lock is disrupted in the active conformation as the cytoplasmic halves of TM3 
and TM6 are pointing in different directions. Further, in the active state, the residues 
Ile184(ECL2) and Phe189(5.38) seem to have a greater distance between them as the 
extracellular loop 2 changes conformation and thus creates more room. Collectively, the 
inactive conformation of the dopamine D2 receptor seems to be more compact compared to 
the active form.  
 
Figure 24: presentation of the dopamine D2 receptor in inactive (left) and active (right) conformation. The inactive 
structure is bound to risperidone while the active is bound to bromocriptine. TM6 and TM3 are coloured dark and 
light green respectively. Pink dotted line in inactive receptor displays a salt bridge (ionic lock) between Glu368 
and Arg132 which is disrupted in the active conformation. ICL2 and ICL3 loop in inactive structure are not shown, 
nor the G-protein in the active form. 
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Further, the structures were superimposed as seen in figure 25 under. The calculated RMSD 
value was 10.10 Å and the biggest deviation between the superimposed structures seemed to 
be the orientation of especially TM6 as the bottom part of this helix did not align as well as 
the other TMs. The rest of the TMs seem to align decently even though none of them are 
100% overlapped as understood from the RMSD value. A low RMSD value, usually around 3 
Å according to the Desmond user manual software (75), indicates a perfect fit.   
 
Figure 25: inactive (green) superimposed on active (red) dopamine D2 receptor. Calculated RMSD value based 
on backbone atoms = 10.10 Å 
 
Additionally, the conformation of aripiprazole (partial agonist) in the dopamine D2 receptor 
was also studied. When it comes to accommodation in the orthosteric binding site, the 
phenylpiperazine part of aripiprazole and the multiple ring system in bromocriptine, occupy 
the same regions, interacting with ECL2, TM3, TM5, TM6 and TM7. The benzioxazole 
moiety of risperidone on the other hand, extends into a deep binding pocket consisting of 
TM3, TM5 and TM6 as seen in figure 26. These residues were mentioned in earlier sections 
presenting protein-ligand interactions. Exclusively, bromocriptine established a stabile 
hydrogen bond to Ser197(5.46) in TM5 and also π − π stacking and water bridge interactions 
to His393(6.55) that were not found in the partial agonist nor antagonist system.  
 





















Figure 26: comparisons of agonist (top left), partial agonist (top right) and antagonist (bottom) in the dopamine D2 
receptor. Ligands and residues are displayed in green and gray respectively. TM6 (blue) and TM7 (purple) were 
partially removed to visualize the accommodation better. All structures are based on the starting structure  
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In the binding site of the serotonin 5-HT2A receptor, the fluorobenzyl ring of pimavanserin 
occupied a region located deep within the receptor as seen in figure 27. Two of the 
interactions that were established in this region were hydrophobic involving Trp336(6.48). 
The chemical structure of pimavanserin deviates excessively from to structures of 
bromocriptine, aripiprazole and risperidone and is much smaller and compact. In addition to 
pimavanserin extending to a deeper region, it also seems to occupy a side extended cavity in 
TM5 with the isobutoxybenzyl group of the drug (to the far left). A side extended cavity like 
this, was not observed in the D2 receptor. Some of the residues in this cavity in close vicinity 
to pimavanserin, included Gly238(5.42) and Leu229(ECL2) contributed with both polar 
(through water molecules) and non-polar interactions. 
  
Figure 27: representation of pimavanserin in the binding site of the serotonin 5-HT2A receptor. Pimavanserin is 
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5 Discussion 
 
The main aim of this present study was to obtain a deeper understanding of how 
antipsychotics interact with specific G-protein coupled receptors at a molecular level, that are 
important for their therapeutic effects (dopamine D2 and serotonin 5-HT2A receptors) and 
adverse side effects (dopamine D2, 5-HT2C and histamine H1 receptors). Firstly, the binding 
affinity and docking scores of 37 antipsychotic drugs for the four G-protein-coupled 
receptors, dopamine D2, serotonin 5-HT2A, 5-HT2C and histamine H1 receptors were studied. 
Secondly, the binding poses of bromocriptine which is an agonist on the dopamine D2 
receptor were compared to the binding poses of aripiprazole and risperidone, a partial agonist 
and antagonist on the same receptor respectively. Pimavanserin, a selective 5-HT2A antagonist 
that is currently only marketed in the U.S as an antipsychotic drug in the treatment of 
Parkinson’s disease psychosis, was also investigated. Methods within computational 
chemistry e.g., IFD and MD simulations were used to accomplish this, and a huge advantage 
is that this approach accelerates and reduces the cost, risk and time it takes to obtain valuable 
information about interesting compounds.   
 
5.1 Induced fit docking 
 
The ability to model IFD provides more accurate conformations compared to standard glide 
docking where ligands are docked into rigid or semi rigid protein structures. Upon binding of 
a drug to its target in reality, the protein structure of the target undergo dynamic changes to 
perfectly accommodate the ligand and this is taken into consideration with IFD. Normally, 
standard glide docking takes much shorter time but the negative side of this is the introduction 
of sensitivity for the reason that only one or very few conformations are used to represent the 
receptor and thereby overlooking all conformational changes in the ligand binding pocket 
induced by a ligand (97). The docking of all 37 ligands in the four receptors (D2, 5-HT2A, 5-
HT2C and H1) was specified with constraints to ensure that the protonated amine in the ligand 
formed a salt bridge interaction with the carboxylate group of Asp(3.32). This interaction is 
known to be important for both binding and activation of agonists and also important for 
binding of antagonists to biogenic amine class A G-protein-coupled receptors (16, 44, 59, 80).  
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Even though IFD is a more time-consuming process than standard glide docking, applying 
constraints definitely reduced the number of poses and helped to further save time during the 
analysis. For the purpose of only docking 37 drugs in four different receptors, this approach 
was sufficient and effective.  
Upon docking of the drugs in their respective target receptors, the binding sites were defined 
in advance by using grids or enclosing boxes. A grid is a box-shaped lattice consisting of 
spaced points surrounding and centered on interesting regions of the target protein and was 
set to include 20 Å3 (98). This was done to ensure that the drugs were incorporated or 
embedded into the regions within the receptor that defined the binding site interacting with 
important residues. This process however has some limitations, among them that by using 
grids, all conformational changes that might occur on both the drug and the target are not 
taken into consideration simply because we only obtain information that is generated after the 
drug is placed into the binding site.  
The results from the IFD, were further based on a “scoring approach” where the binding 
affinity or energy of a protein-ligand complex was calculated and ranked. To process the 
number of molecules involved in a docking process, the scoring calculations have to be rapid. 
However, they also have to be accurate enough to give good measures of the binding 
affinities. This is a difficult compromise as increased computational speed can include 
applying simplifications or short cuts as well as assumptions. This in turn, reduce the 
accuracy, hence, the evaluation of a drugs affinity to its target is affected (31, 73). Force fields 
that estimate binding affinities by summarizing the contribution of different interactions (such 
as vdW and electrostatic interactions) and bond bending/angles/stretching etc, were applied 
which creates an uncertainty. This is further discussed in detail later.  
Another drawback with scoring function is that water molecules were not taken into 
consideration although the biological systems are located in aqueous environment. Water 
molecules can form interactions with surrounding molecules including the drug, and thereby 
have an impact on the docking score (60, 83, 84).  Finally, all of the drugs that were docked 
were alkaline with pKa values above 7 (common for alkaline compounds) while the aqueous 
environment utilized in the process pH of 7.0 ± 2.0. Due to differences in acidity in the 
environment and the actual compounds, the drugs exist in both protonated and unprotonated 
states. It is the protonated state of the drug that establishes a salt bridge interaction to Asp3.32 
(in all of the aminergic receptors used in this thesis), hence that state is docked. The 
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unprotonated state is not payed regards to, and the fraction of unprotonated versus protonated 
state remains unknown. Determination of the concentration needed of the drug to occupy 50 
percent of the receptors is therefore not 100 percent accurate.  
 
5.1.1  The context between receptor binding profiles and side effects 
 
Among the most recurrent side effects of antipsychotic drugs levomepromazine, 
prochlorperazine, quetiapine, olanzapine, risperidone and aripiprazole are sedation or 
drowsiness. Sedation and drowsiness are mainly associated with antagonism on the histamine 
H1 receptor according to previous articles (32, 93). This can also be seen in light of the 
affinity values reported for these drugs on the histamine H1 receptor. The reported Ki values 
of levomepromazine, prochlorperazine, quetiapine, olanzapine, risperidone and aripiprazole 
on the H1 receptor presented in table 4, were 0.6 nM, 6.0 nM, 2.2 nM, 0.09 nM, 3.5 nM and 
25.1 nM respectively. Thus, mostly classified as high affinity with the exception of 
aripiprazole that would be classified as a moderate affinity drug on the histamine H1 receptor. 
The induced fit docking scores were -8.4 kcal/mol for levomepromazine, -11.3 kcal/mol for 
prochlorperazine, -10.9 kcal/mol for quetiapine, -9.8 kcal/mol for olanzapine, -9.5 kcal/mol 
for risperidone and -9.6 kcal/mol for aripiprazole. Twenty of the 30 drugs with reported 
binding affinity values from PDSP on the H1 receptor could be classified as high affinity 
drugs. This more or less demonstrates why many patients experience sedation or drowsiness 
upon antipsychotic treatment. For patients that are agitated and suffer from acute psychosis 
though, these side effects can have a beneficial effect and are generally more tolerable (32). 
Further, such side effects tend to decrease with continued use and are «mild» compared to 
other side effects described later in this chapter.  
The histamine H1 receptor is a G-protein-coupled receptor with many structural similarities to 
both the dopamine and serotonin receptors such as the conserved CWxP, PIF, NPxxY and 
DRY motifs as well as a conserved disulphide bridge between ECL2 and the top of TM3 (56, 
57). However, according to Shimamura et al. 2012 (80), the overall size of the ligand binding 
pocket of the histamine H1 receptor seems to be more spacious because the ECL2 constitute 
more residues which increases the distance between TM3 and TM5 compared to dopamine 
and serotonin receptors. This ultimately results in better accommodation of histamine H1 
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selective antagonists such as doxepin, a tricyclic antidepressant, as they tend to be quite bulky 
and large. The main residues that are involved in interactions with doxepin are Asp107(3.32) 
forming a salt bridge, and Ile115(4.40), Phe24(6.44), Trp428(6.48) and Phe432(6.52) 
participating in hydrophobic interactions such as 𝜋 − 𝜋 stacking. For reference, the reported 
Ki value of doxepin on the H1 receptor is 0.09 nM (99) and comparably to the antipsychotics 
discussed in the present study, the most pronounced side effect of doxepin too, is sedation.  
Extrapyramidal side effects (EPS) being acute dystonia, tardive dyskinesia, akathisia, rigidity, 
tremor and bradykinesia are usually explained by antagonism at D2 receptors especially in the 
nigrostriatal pathway and are thus more prevalent with TAPs (11, 18, 100). It is believed that 
the severity of EPS produced by the drugs, increases with its affinity for the D2 receptor (11). 
Levomepromazine and prochlorperazine are two of the most prescribed TAPs in Norway and 
their Ki values on the dopamine D2 receptor are 5.9 nM and 0.2 nM respectively. This renders 
them both high affinity and using these drugs over long time increases the risk of developing 
EPS. AAPs on the other hand, act by simultaneous antagonism on the 5-HT2A receptor, 
decreasing the inhibitory effect serotonin has on the dopaminergic system in the nigrostriatal 
pathway  and thereby reducing the severity of dopamine D2 antagonist-induced EPS (44). 
Therefore, the frequency of EPS in AAPs in general is lower. In the present study, some 
examples of AAPs are risperidone, olanzapine, quetiapine, aripiprazole and clozapine. The Ki 
values for risperidone for instance on the D2 and 5-HT2A receptor were 0.3 nM and 0.1 nM 
respectively, which means its binding affinities to both these receptors are high. This is in 
good agreement with the findings in Kimura et al 2019 (44). The same trend was seen in 
Yonemura et al 1998 (93) and Kondej et al 2018 (47).  
Besides side effects such as such as sedation and motor disturbances i.e., EPS, some 
antipsychotic drugs are further known to affect metabolic regulation. Endocrine disturbances 
can occur by antagonism on D2 receptors in the anterior pituitary gland, leading to 
hyperprolactinemia and abnormal breast enlargement in both genders. This side effect is 
much more prevalent in TAPs compared to AAPs (101). Another effect, antipsychotic-
induced weight gain, can quickly result in obesity which in the worst case can develop into 
diabetes (102, 103) . It is believed that this most likely involves antagonism at both the 
histamine H1 receptor and the 5-HT2C receptor and is a result of altered glucose tolerance as 
well as increased food intake (11, 18, 103-105).  
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Clozapine has moderate affinity for the dopamine D2 receptor (Ki value of 44 nM) but high 
binding affinity to 5-HT2A, 5-HT2C and histamine H1 receptors with reported values of 5.4 
nM, 9.4 nM and 1.1 nM respectively. It is associated with absence of EPS but a significant 
risk of weight gain. The affinity of olanzapine on the 5-HT2C and histamine H1 receptors was 
4.1 nM and 0.09 nM respectively. These findings confirm what was found in previous articles 
(11, 42, 103-105) where it was concluded that clozapine and olanzapine are amongst the 
antipsychotics with most pronounced risk of weight gain. In two articles (105, 106) where 
antipsychotic drug-induced weight gain was investigated, it was concluded that individuals on 
treatment with clozapine and olanzapine, gained a mean of approximately 12 kg and 7-12 kg 
respectively over a period of 12 months. Nasrallah et al (106) further stated that compared to 
clozapine and olanzapine, use of risperidone was associated with a mean weight gain of 2-3 
kg over the same period.  Additionally, in 2004 Bitter et al found no statistically significant 
difference in weight gain between clozapine and olanzapine (107). The similar behaviour 
observed with clozapine and olanzapine is probably due to the similarities in their chemical 
structures, figure 8.  
Interestingly, haloperidol which is a TAP, has much lower affinities for histamine H1 and 5-
HT2C receptors with Ki values of 1800 nM and >10000 nM respectively and is known to have 
an insignificant effect on weight gain (38, 105). Patients on AAP treatment gained more 
weight than patients on TAPs according to a Cochrane meta-analysis from 2010 (108). 
However, the same pattern was not observed for other TAPs like levomepromazine and 
prochlorperazine as their affinities were moderate to high on H1 and 5-HT2C receptors. 
Finally, it is worth noting that despite not being mentioned in this study, TAPs are commonly 
divided into low- and high potency drugs which are equally efficacious. The groups 
nonetheless differ in tolerability and side effects and can explain why different trends are seen 
in different TAPs even though they belong to the same category (38).  
Pimavanserin is very selective to the serotonin 5-HT2A receptor with a Ki value of 0.087 nM 
and 0.44 nM for the serotonin 5-HT2C receptor (92). No appreciable affinity values (Ki value 
over 300 nM) were reported for pimavanserin on any other aminergic receptor, and one can 
speculate that that is the reason why most of the common side effects of pimavanserin differ 
from those of conventional antipsychotics. Some of these side effects include nausea and 
constipation. However, more severe psychiatric disturbances upon pimavanserin treatment 
such as hallucination, delirium and gait disturbance, have been reported (92). 
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For many years, clozapine has been the gold standard in treatment-resistant schizophrenia and 
related disorders when treatment with other antipsychotic drugs remains inadequate (18, 102, 
103). In addition to previously mentioned side effects, agranulocytosis and neutropenia 
(lowered white blood cell count) are rare, yet life-threatening side effects that are estimated to 
occur in 1-2 percent of clozapine treated patients (46). These drug-induced haematological 
reactions are most likely results of hypersensitivity reactions and not directly linked to 
binding affinity on any of the respective receptors. The exact mechanism remains unclear, but 
one theory proposes that antibodies against neutrophils may be produced upon treatment with 
clozapine which ultimately leads to a deficit in white blood cells (109). It is impossible to 
predict the risk of these side effects so diligent monitoring is required. The risk of 
agranulocytosis is however believed to be higher among women and increases with age (46).  
Just like with all drugs, it is more than the actual drug that determines whether a patient 
develops side effects or not.  Background variables like gender, genetics and age are 
important factors that help explain the reasons why some patients are more prone compared to 
others. The severity of the side effects is extremely difficult to prognosticate, and in some 
cases, the side effects occur in the beginning of the treatment but lessen with time. Other 
times the side effects are so severe that discontinuation is the only option. Receptor binding 
profiles are partially useful in predicting side effects but are not alone advance enough to 
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5.2 Molecular dynamics simulations  
 
In part two of this study, MD simulations were run, and detailed descriptions are provided in 
earlier chapters. In comparison to IFD, the MD simulations incorporated information about 
structural conformational states important for understanding the pharmacology and 
physiology of GPCRs, that could not be obtained solely based on IFD. Further, the MD 
simulations yielded valuable information about the strength of ligand-protein interactions in 
terms of contact frequencies. This was very helpful in the identification of key interactions 
established between the ligands and the receptors, especially when comparing the intrinsic 
activity of different ligands on the same receptor. Ultimately, utilizing MD simulations gave 
insights into the differences between activated and inactivated D2 receptor, highlighting some 
of the interactions that were formed. An advantage with the MD simulations was its ability to 
successfully carry out the simulations despite the fact that the systems were quite large, 
consisting of over 100,000 atoms each.  
Conclusively, MD simulations have improved performance compared to IFD and also allows 
simulation of larger systems over longer periods of time.  However, the running time can be 
up to several weeks, which sometimes is regarded as a limitation (72). This method is more 
resource-consuming than docking studies but in return, it provides a much higher accuracy 
and reliability.  
One drawback that limits the usability of MD simulations in this thesis, is the use of force 
fields because they are generally based on approximations and experimental measurement and 
are thus not 100 percent accurate. The OPLS_2005 force field was utilized, however, there 
are newer and more updated force fields such as OPLS3e that achieve a higher level of 
accuracy in e.g., predicting protein-ligand binding. The improvements that have been 
introduced, include extensive parameterization of valence and torsional terms, virtual sites 
that better compute partial charges and represent lone pairs and charge distributions as well 
(110). These are indeed enhancements that lead to improved performance, nevertheless, there 
is always room for improvement. As more knowledge of even more complex chemical 
systems is obtained, new challenges with the fidelity of force fields are exposed. Further, as 
more reference data become available, additional refinements like improved torsion types to 
better determine e.g., conformation energies, will be necessary to ensure more robust and 
meaningful results (110).  
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Another important challenge is the simulation timescale step which is the time length between 
evaluations of the potential. In many cases the timestep is not small enough to capture the 
fastest relevant molecular events and movements, and one fears that valuable information is 
lost or left out. The consequence of this would be poor characterization of the proteins 
dynamic behaviour. There are techniques such as simplifying the models, metadynamics and 
simulated annealing that can be applied to overcome this limitation and fortunately, advances 
in algorithms, hardwares and softwares have increased the effectiveness of timesteps (72). 
The application of MD simulations definitely provides valuable information that is useful in 
particularly drug design and is less resource consuming compared to experimental methods. 
This approach is faster, cheaper and more accessible and can for instance improve lead 
optimization e.g., by refining them to improve their selectivity based on the dynamic nature 
investigated with MD simulations (111). 
 
5.2.1 The structural stability of the systems 
 
Among the important parameters used to evaluate the structural changes that occurred during 
the simulations, are RMSD and RMSF. RMSF was also used to describe relative mobility of 
specific regions of the systems. Like mentioned in earlier sections, ligand-free systems were 
constructed in addition to the ligand-bound systems to investigate the influence the respective 
ligands had on the dynamic profiles of the proteins. Regarding the RMSDs, collectively, the 
ligand-bound structures (except pimavanserin in 5-HT2A receptor) were less stable compared 
to the ligand-free systems. The reported RMSD values were in general a bit higher in the 
ligand-bound systems as well. Further, in the ligand-bound systems, the plots seemed to 
increase in the beginning before establishing a stable path out the simulation. Oppositely, in 
the ligand-free systems, the plots seemed more stable in the beginning before slight increasing 
were observed towards the ends of the simulations.  
The overall RMSD values for the ligand-free systems were lower than the ligand-bound, 
which further renders them more stable, as seen in figure 10 and 11. Based on this, it is 
reasonable to assume that the presence of ligands in the binding cavities, affect the dynamic 
and structural behaviours of both the dopamine D2 and serotonin 5-HT2A receptors. This is 
most likely a result of interactions that were formed between the drugs and the binding site 
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residues within the receptors. It was expected that the biggest changes would be seen in the 
partial agonist and especially agonist plots, simply because drugs with these intrinsic 
activities are expected to have a significant influence on their target. Pimavanserin and 
risperidone are both antagonists on their respective receptors and their plots seem more stable, 
ergo they seem to affect their targets less. However, it is important to elucidate the fact that 
the G-protein was coupled to the receptors in the bromocriptine and aripiprazole systems, but 
not in the pimavanserin and risperidone systems. It is very possible that the G-protein also 
had an influence on the overall plots and RMSD values. 
When it comes to the RMSF plots for all of the systems, they were in good agreement with 
what is already known about secondary structures. The highest peaks and biggest fluctuations 
were observed in the loop regions and particularly the amino and carboxyl terminuses as these 
are studied to be the most flexible and variable segments (57, 72). Regions with less peaks 
and low RMSF values corresponded to the transmembrane helices where the amino acids are 
stabilized by the secondary structure, similarly to what was discovered by Salmas et al 2016 
(16). The regions representing the beta strands were also relatively low compared to the loop 
regions and in this case, beta strands were only observed in the systems containing the G-
protein. Loops are generally more exposed to the surface compared to other secondary 
structures which are hidden in cores and more conserved. Thus, loop are usually more 
susceptible to changes, often have lower sequence conservation and can adopt many different 
structural forms (56). 
Both the RMSD and RMSF plots for aripiprazole revealed higher flexibility compared to the 
other plots correspondingly to the findings in Salmas et al (16). In the same article they 
suggested that the reason for this was the extended structure of the drug and hydrogen bonds 
that were forming and breaking between some of the TMs. However, this was not 
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5.2.2 Protein-ligand interactions 
 
The interactions of bromocriptine, aripiprazole, risperidone and pimavanserin were 
investigated based on the results from the MD simulations. What was seen in all systems, was 
the ability to make a salt bridge interaction between protonated nitrogen in the drugs and 
conserved Asp(3.32) in the dopamine D2 and serotonin 5-HT2A receptor. From earlier, it is 
known that particularly this interaction is a part of the aminergic receptors pharmacophore 
and crucial for receptor binding (16, 44, 47, 59, 80, 112, 113). The other interactions that 
seemed to be necessary for receptor binding included both polar and non-polar interactions 
such as hydrogen bonds, hydrophobic interactions (𝜋 − 𝜋 stacking, vdW and cation- 𝜋 
interactions) and water bridges. This was described in detail in earlier sections. A comparison 
of bromocriptine, aripiprazole and risperidone in the dopamine D2 receptor revealed that 
bromocriptine established a stable hydrogen bond to Ser197(5.46), π − π stacking and water 
bridge interactions to His393(6.55) that were not found in the partial agonist nor antagonist 
system. The hydrogen bond established between bromocriptine and Ser197(5.46) has been 
reported to be necessary for receptor activation (64, 67, 113) and was observed in both of the 
simulations that were run with bromocriptine in the present study. 
Interestingly, in the aripiprazole-D2 receptor complex, two stable hydrogen bonds were 
observed with Cys182 (in ECL2) that were not observed in any of the other systems. These 
hydrogen bonds were present throughout the simulation which most likely means they have a 
significant importance in the effect of aripiprazole on the dopamine D2 receptor. Activation of 
the dopamine D2 receptor, includes interactions with serines in TM5 (Ser5.42 or Ser5.43 or 
Ser5.46) and these were lacking in the aripiprazole- D2 receptor complex. Thus, this is likely 
to result in reduced receptor activation which can contribute to the reason why aripiprazole is 
classified as a partial agonist.  
Moving further, it was observed a hydrogen bond with Ser193(5.42) in the risperidone- D2 
receptor complex that did not seem to be crucial due to the fraction of approximately 20%. 
Compared to bromocriptine and aripiprazole, risperidone did not establish any hydrogen 
bonds of significant importance and earlier publications (16, 44, 59), have not either 
mentioned hydrogen bonds as important for risperidone binding to an inactive state 
conformation of the D2 receptor. Other interactions however, such as hydrophobic 
interactions (vdW and π − π stacking interactions) with the hydrophobic aromatic network in 
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the D2 receptor, have been mentioned and is in good agreement with the findings of the 
present study. In contrast to the active structure of the dopamine D2 receptor, the inactive 
structure seems to be more compact which also allows for the «ionic lock» to constrict the 
receptor. Similarly to what was reported by Salmas et al in 2015 (59), the more spread-out 
active structure on the other hand, reveals an outward movement of TM5 and TM6 which 
creates a suitable site for the binding of a G-protein at the bottom of these helices as seen in 
figure 23.  
Regarding pimavanserin, its binding profile to the serotonin 5-HT2A receptor in the present 
study included hydrogen bond and salt bridge to Asp155(3.32), hydrophobic interactions to 
Trp336(6.48), Phe339(6.51), Leu229(ECL2) among others. Water bridges were created to 
especially Leu229(ECL2) and Asn343(6.55). Kimura et al (44) reported similar findings in 
2019.  
 
5.2.3 Binding modes of the antipsychotic drugs 
 
When it comes to the binding poses, the different antipsychotic drugs seem to bind and 
occupy different regions which probably has something to say for their binding affinities and 
intrinsic activities. Firstly, it is relevant to mention that multiple previous publications have 
categorized the drugs into different groups mainly based on their structures. The structures of 
the antipsychotic drugs are shown in figure 8. Class I drugs, such as clozapine, olanzapine 
share bulky structures while class II drugs like aripiprazole and risperidone have a more 
extended chemical structure (59, 67). In this case, only based on structure, pimavanserin is 
more similar to class II drugs. Class II drugs, risperidone in particular, extends into a deep 
binding pocket in the dopamine D2 receptor, which is situated below the actual orthosteric site 
according to Wang et al 2018 (79) and also confirmed in the present study. The predicted 
binding site of antagonists such as risperidone in the dopamine D2 receptor, includes the 
extended deep pocket and is found to consist of TM2, TM3, TM4, TM6 and TM7 with 
minimal interactions to residues in TM5 like described earlier (64). Further, Kimura et al 
2019 (44) pointed out that pimavanserin due to its structure, occupied a side extended cavity 
which they suggested contributed to the high selectivity for the 5-HT2A receptor. This is 
because the side extended cavity of other serotonergic receptors most likely are too shallow to 
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accommodate pimavanserin. However, due to short time, this was not investigated thoroughly 
in the present study.   
Bromocriptine and aripiprazole did not extend into a deeper binding pocket, but they occupied 
the same regions in the orthosteric binding pocket, interacting with TM3-TM6. These TMs 
are described to make up the actual orthosteric binding pocket (67). Further, a part of the 
structure of aripiprazole seems to additionally occupy an extended binding pocket located 
closer to the extracellular surface in a similar manner to risperidone. This binding pocket is 
different from the binding pocket observed below the orthosteric binding pocket. A figure 
displaying the comparison of the discussed ligands is provided in earlier sections, figure 25. 
Kling et al (114) described similar findings in 2014.   
A quite interesting feature that was observed in all frames for all the drugs from the 
conformational transition analysis (figures 2-5 supplementary material), was the movement of 
water molecules throughout the MD simulations. Some of the hydrogen bonds that were 
established in the present study were mediated through water molecules as seen in figures 15-
23. Other water molecules interacted with each other in addition to residues in the binding 
pocket correspondingly to what was explained by Venkatakrishnan et al in 2013 (115). 
Because water molecules were present in the binding site of all of the systems, it can be 
assumed that they play an important role in the binding of drugs to their target receptor. 
According to Zuk et al (116) activation of G-protein-coupled receptors correlates with the 
formation of continuous internal water pathways. In 2019, Venkatakrishnan et al published 
their results where they concluded that the water molecules observed in the crystal structures 
of GPCRs are not equal. While some of these molecules are stable, most are mobile. They 
further suggested that a network of hydrogen bonds was formed by stable water molecules 
located near the G-protein binding site, which seemed to be conserved in class A GPCRs. 
However, the water molecules in the ligand binding pocket varied among the class (117).  
In contrast to previous articles that investigated the effect of water molecules in whole 
systems (i.e., the whole proteins including both orthosteric and G-protein binding site), here, 
only water molecules that were present in the ligand binding sites were studied. The binding 
sites of the dopamine D2 and serotonin 5-HT2A receptors in the current study, were set to 
include residues and waters within 5 angstroms from the ligand. For example, in the 
bromocriptine system, 24 water molecules were observed in frame 1 while 26, 43, 31 and 34 
water molecules were observed in frames 1001, 2001, 3001 and 4001 respectively. None of 
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the water molecules remained at the same position throughout the whole simulation in any of 
the systems MD was run on. This can confirm the theory about water molecules located in the 
ligand binding sites being highly mobile (117). In frame 1 in the bromocriptine – D2 complex, 
water molecule SPC15 made direct interactions to a carboxylate group in bromocriptine. Both 
SPC19410 and SPC21489 interacted with Ile184 (ECL2) which then established a hydrogen 
bond to bromocriptine as seen in supplementary figure 6. Many of the water molecules in the 
binding sites of both the D2 and 5-HT2A receptors additionally interacted with each other as 
expected (115).  
Finally, all of the ligands were accommodated in the orthosteric binding sites of their 
respective targets and like discussed, some of the ligands occupied additional spaces in the 
receptors. Unfortunately, in this thesis, the role of ECL2 was not taken into consideration but 
it is believed to have an important functional role in deciding how the ligands bind to their 
target receptors. ECL2 is known to play an important role in ligand recognition, selectivity 
and activation (57, 118). In the dopamine D2 receptor, residues in ECL2 such as 
Ile183(ECL2), Ile184(ECL2) and Cys182(ECL2), as well as Leu229(ECL2) in the serotonin 
5-HT2A receptor, were involved in stable interactions with bromocriptine, aripiprazole and 
pimavanserin. This further shows the importance of ECL2 in receptor activation. This equated 
to the observations made by Kling et al in 2014 (114).  
During activation of the G-protein-coupled receptors, it is believed that the loop adopts 
different conformations. In the beginning, the loop adopts an open conformation to 
accommodate the entry of the ligand into the orthosteric site. Following accommodation, the 
ECL2 then closes over the orthosteric site like a lid and is stabilised by contributing to 
interactions with the ligand (56, 57). The interactions formed between the drug and ECL2, are 
important for the specificity aspect as well. Interestingly, the interactions formed between the 
ECL2 and bromocriptine and aripiprazole were mostly hydrogen bonds. A small fraction of 
the interactions between bromocriptine and Ile184(ECL2) in the dopamine D2 receptor were 
hydrophobic. Furthermore, the tiny fraction of interactions that were seen in the risperidone-
D2 receptor (antagonist) were hydrophobic. In the pimavanserin-5-HT2A receptor complex, 
the interactions between Leu229(ECL2) and the drug, were both polar and non-polar. 
According to Wheatly et al (56), Peeters et al (57) and Kling et al (114), some of the 
differences in the ECL2 in agonists versus antagonist lies in the actual geometry of the loop 
as this further affects how the drug is accommodated but also what interactions that are able 
to form. 
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5.3 Future expectations  
 
Antipsychotics drugs are commonly used across the globe in the treatment of disorders such 
as psychosis and schizophrenia. Many individuals suffering from these disorders begin 
treatment with antipsychotics and remain on treatment for long periods of time. In addition to 
producing effects that alleviate the symptoms, antipsychotics unfortunately produce side 
effects. Some of them are transient, while other may develop into more adverse reactions that 
either require medical intervention or discontinuation like it has been discussed in this thesis. 
For example in treatment – resistant schizophrenia, clozapine is the “gold standard” 
medication of choice but serious adverse effects like weight gain and agranulocytosis are 
associated with this drug (32). Therefore, it is of great interest to develop effective drugs that 
are deficient of such side effects.   
Aminergic receptors such as the dopamine D2, 5-HT2A, 5-HT2C and histamine H1 receptors, 
have high structural conservation of the ligand binding sites which creates a challenge in the 
development of receptor-selective drugs. The binding sites in these receptors greatly overlap 
and explains why most antipsychotics produce side effects in addition to their ability to cause 
favourable reactions. The similarities between the aminergic receptors may contribute to 
reduced receptor selectivity for drugs that bind to multiple receptors, such as atypical 
antipsychotics. However, there have been discovered a few structural differences between the 
aminergic receptors that can be used as starting points to develop more selective drugs.  
For instance, the 5-HT2A receptor has an extended side cavity between TM4 and TM5 close to 
the orthosteric site with Gly238(5.42) in the entrance. This position is occupied by Ala(5.42) 
in dopamine D2, Ile(5.42) in 5-HT2C and Lys(5.42) in histamine H1 receptors. Compared to 
glycine, the side chains of alanine, isoleucine and lysine are larger and block the entrance of 
the side-extended cavity in a way that drugs cant extends into this side cavity. In a study 
where the docking poses of pimavanserin were studied (44) it was revealed that the 
isobutoxybenzyl group of pimavanserin occupied the side cavity. They also did a mutagenesis 
study where Gly238(5.42) was substituted into a serine which resulted in decreased affinity 
and activity. 
When it comes to the inactive dopamine D2 receptor structure (in complex with risperidone, 
figures 19-20) compared to the 5-HT2A receptor (figure 22), it is clear that the involvement of 
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ECL2 in 5-HT2A receptor for ligand binding is important. In the active dopamine D2 receptor 
structure in complex with bromocriptine and aripiprazole, residues Ile184(ECL2) and 
Cys182(ECL2) in this loop covered the ligand binding site and created stable interactions 
with the drugs. However, in the inactive structure of the D2 receptor, the ECL2 is oriented 
away from the ligand binding site in a way that does not facilitate stable contacts between the 
drug and the receptor (44). The opposite is observed in the pimavanserin – 5-HT2A receptor 
complex where interactions with Leu229(ECL2) are amongst the most stable and persistent 
throughout the MD simulation. Thus, this means that interactions established between the 
drug and ECL2 in the 5-HT2A receptor, are necessary for drug binding and for the activity 
whereas it is not as important for the activity of risperidone in the dopamine D2 receptor. It 
therefore seems like the conformation that ECL2 can adapt to accommodate both the drug and 
residues in close vicinity, is specific to different receptors. Taking this difference into 
consideration during drug design may contribute to increased specificity for one receptor over 
the other.  
Moving further, the histamine H1 receptor also has some unique features that differentiates it 
from other aminergic receptors. While ECL2 in the histamine H1 consists of 22 residues, the 
ELC2 of D2, 5-HT2A and 5-HT2C receptors consists of 12, 13 and 14 residues respectively. 
Due to the length of the ECL2 in the H1 receptor, the distance between TM4 and TM5 is 
increased which again creates more space within the ligand binding pocket. Shimamura et al 
(80) described similar findings and proposed that large and bulky drugs could be well 
accommodated within this binding pocket since it is more spacious. An anion binding site 
located at the entrance of the ligand binding site, consisting of a phosphate ion, that is specific 
to histamine H1 receptor, has additionally been discovered. It has further been suggested that 
the phosphate ion may serve as a positive modulator of ligand binding as the affinities for 
histamine and some H1-antagonist, increased with the presence of the phosphate. Among 
some of the residues in the histamine H1 receptor believed to coordinate the phosphate ion are 
Lys191(5.39), Tyr413(6.51) and His450(7.35) and the phosphate ion itself is seemingly 
involved in ionic interactions with drugs (80).  
Even though most class A GPCRs share many structural similarities and conserved residues, 
there are some features that are unique to each of them like what has been discussed. By 
investigating and performing more structural studies on each of these receptors, more 
differences may be revealed which further simplifies the distinction of the receptors.  In those 
cases where it is known what interactions between the drug and receptor that increase the 
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stability and activity of the drug, it would be reasonable to take advantage of that to ensure 
desired interactions but also avoid them. In the example of antipsychotic drugs where 
antagonism of the histamine H1 receptor is associated with certain side effects, it would make 
sense to try to avoid drug-protein contacts that improve the drugs affinity to the receptor. On 
the contrary, it is an extremely difficult compromise to establish desirable interactions (to 
ensure sufficient activity), avoid undesirable interactions as well as establish interactions that 
are selective enough to avoid deleterious “off-target” interactions with related targets. 
However, this has successfully been done, resulting in drugs like for instance pimavanserin, 
the only non-dopaminergic antipsychotic drug (in treatment of Parkinson’s disease 
psychosis).  
Understanding of functional selectivity or biased agonism in addition to increased knowledge 
regarding the signalling pathways of GPCRs, represents promising avenues that in the future 
will lead to the development of more specific drugs. This way, one can develop compounds 
that are biased for either G-protein or arrestin signalling and thereby promote the beneficial 
pathway and subsequently inhibit potential deleterious pathways. Lysergic acid diethylamide 
(LSD) and β2-antagonist carvedilol are two examples of compounds that display biased 
agonism. Carvedilol is a β2-adrenoreceptor antagonist used in the treatment of heart failure. 
The antagonist property of the drug inhibits the toxic effects the endogenous ligands 
(noradrenaline and adrenaline) have on the heart mediated by G-protein, while it also has 
cardioprotecting properties by stimulating cell survival through the arrestin pathway (119). 
Similarly, LSD differentially activates both the G-protein and arrestin signalling pathways on 
the 5-HT2B receptor and is believed to recruit arrestin over the activation of G-proteins 
resulting in hallucinations and altered thoughts (120). It is now understood that some drugs 
have the capacity to preferentially activate either G-protein signalling or arrestin-signalling. 
The next step would be to get a clearer understanding of the molecular basis of the coupling 
and how the drugs selectively influence different conformations leading to the activation of 
either pathway. 
One way to gain insight into this can be by obtaining protein structures with even higher 
resolution than current and also protein structures with different ligands in the orthosteric site 
coupled to diverse binding proteins. Additionally, it would be interesting to obtain protein 
structures of the GPCRs in different states such as fully -, partially activated and inactivated 
receptor to understand how different drugs modulate function. Finally, in order to design new 
drugs based on the properties and 3D structure of different GPCRs like discussed above, a 
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strategy known as structure-based drug design (SBDD), can be utilized. With this strategy, 
the features of the target are exploited to design a drug that potentially establishes crucial 
drug-receptor interactions (121). Ligand-based drug design (LBDD) is another approach in 
drug design that rather depends on the physiochemical properties of the drug of interest when 
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6 Conclusion  
 
Class A GPCRs are interesting drug targets as ubiquitous neurotransmitters such as dopamine 
and serotonin bind to them and they are additionally associated with a variety of disorders, 
including psychosis disorders, schizophrenia and depression. In summary, computational 
approaches were applied to investigate the binding affinities and interactions between 
antipsychotic drugs and class A GPCRs dopamine D2, 5-HT2A, 5-HT2c and histamine H1 
receptors mediating antipsychotic effects as well as important side effects. The docking scores 
from IFD were viewed in context of the binding affinities (Ki value) of the drugs to the 
different receptors. The results indicate that there is a context between binding affinity and 
reported side effects that could be used to understand and distinguish between typical and 
atypical antipsychotics. Moreover, the development of novel drugs in the treatment of for 
example schizophrenia is highly needed as many people experience side effects as a result of 
off-target effects involving 5-HT2C, histamine H1, 1 adrenergic and muscarinic receptors.  
MD simulations revealed that antipsychotic drugs with different intrinsic activity, bind to the 
dopamine D2 receptor in distinct ways, thus ligand-specific conformations were captured. One 
of the findings showed that an agonist like bromocriptine on the dopamine D2 receptor, 
established a stable hydrogen bond to Ser197(5.46) that was not maintained in the partial 
agonist nor antagonist systems. This in particular is believed to help explain the reduced 
efficacy observed with aripiprazole. Further risperidone (antagonist on dopamine D2 receptor) 
extended into a deep binding pocket in the receptor unlike the agonist and partial agonist 
aripiprazole, establishing hydrophobic interactions with Trp386(6.48), Phe382(6.44) and 
Phe389(6.51) among others. Aripiprazole seemed to bind to the dopamine D2 receptor in 
ways that resembled the binding modes of both an agonist and antagonist. Ultimately, the 
concept of functional selectivity or biased agonism which is also the proposed mechanism of 
action of aripiprazole, takes into account a ligands ability to activate different signalling 
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7 Supplementary material  
 
 
Table 1: overview table showing the classification of dopamine receptors with subtypes, functional role, G-protein 
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Table 2: overview table showing the classification of serotonin receptors with subtypes, functional role, G-protein coupling and agonists/antagonists on the receptors (18).  
 
 







































 Figure 2: in dept presentation of the ligand-residue contacts formed in the five frames (1, 1001, 2001, 3001 and 4001) described in the results section for the conformational 
transition analysis. Bromocriptine is coloured in blue, lilac, green, beige and red for each frame respectively while binding site residues are coloured gray. Yellow dotted lines 
represent hydrogen bonds, red spheres are water molecules, blue dotted lines are 𝜋 − 𝜋 stacking interactions, pink line is ionic interaction. 
 













Figure 3: in dept presentation of the ligand-residue contacts formed in the five frames (1, 1001, 2001, 3001 and 4001) described in the results section for the conformational 
transition analysis.  Aripiprazole is coloured in blue, lilac, green, beige and red for each frame respectively while binding site residues are coloured gray. Yellow dotted lines 
represent hydrogen bonds, red spheres are water molecules, blue dotted lines are 𝜋 − 𝜋 stacking interactions, pink line is ionic interaction while the purple dotted line is a 
halogen interaction. 
 













Figure 4: in dept presentation of the ligand-residue contacts formed in the five frames (1, 1001, 2001, 3001 and 4001) described in the results section for the conformational 
transition analysis. Risperidone is coloured in blue, lilac, green, beige and red for each frame respectively. Yellow dotted lines represent hydrogen bonds, red spheres are water 
molecules, blue dotted lines are 𝜋 − 𝜋 stacking interactions, pink line is ionic interaction and green represents  𝜋 − 𝑐𝑎𝑡𝑖𝑜𝑛 interaction.
 













Figure 5: in dept presentation of the ligand-residue contacts formed in the five frames (1, 1001, 2001, 3001 and 4001) described in the results section. Pimavanserin is 
coloured in blue, lilac, green, beige and red for each frame respectively while binding site residues are coloured gray. Yellow dotted lines represent hydrogen bonds, red 
spheres are water molecules, blue dotted lines are 𝜋 − 𝜋 stacking interactions, pink line is ionic interaction and green represents  𝜋 − 𝑐𝑎𝑡𝑖𝑜𝑛 interaction
 













Figure 6: water molecules in the orthosteric site in frame 1 of the bromocriptine – D2 receptor simulation. 
Bromocriptine is displayed in blue, surrounding binding site residues in gray and water molecules in red. 
Hydrogen bonds are shown as yellow dotted lines and the rings highlights the interactions established between 
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